

SUPPORTING INFORMATION FOR

**Development of novel Gemini-cholesterol analogues for Retinoid-related
Orphan Receptor**

Uxía Gómez-Bouzó,^a Alioune Fall,^a Judit Osz,^b Yagamare Fall,^a Natacha Rochel^{*b} and Hugo Santalla^{*a}

^aDepartamento de Química Orgánica, Facultad de Química and Instituto de Investigación Sanitaria Galicia Sur (IISGS), University of Vigo, Campus Marcosende, 36310 Vigo, Spain, ^bDepartment of Integrative Structural Biology, IGBMC - CNRS UMR7104 - Inserm U964, 1, rue Laurent Fries, 67400 Illkirch, France.

hsantalla@uvigo.es; rochel@igbmc.fr;

Table of Contents

1. Experimental part	2
2. ¹ H-NMR and ¹³ C-NMR Spectra	49
3. X-Ray Spectra	93
4. Supplementary figures	96

1. Experimental part

1.1. General procedures (Chemistry)

Solvents were purified and dried by standard procedures before use. The evolution of the reactions was followed by thin layer chromatography (TLC) with Merck 60 F₂₅₄ silica gel plates on aluminium support. The chromatoplates were visualized by exposure to UV light (254 nm) and developed by treatment with a staining solution and subsequent heating. The staining solution used was *p*-anisaldehyde (4.2 mL) in AcOH (3.75 mL), H₂SO₄ (12.5 mL) and MeOH (338 mL). For purification by pressure column chromatography was used Merck silica gel 60 (230-400 mesh). The products were previously mixed with silica gel before being introduced into the column.

Optical rotations were obtained using a JASCO P-2000 polarimeter. ¹H NMR and ¹³C NMR spectra were recorded on a Bruker AMX 400 (400 MHz for ¹H and 100 MHz for ¹³C). Chemical shifts (δ) were measured in ppm relative to TMS $\delta = 0$ for ¹H or to chloroform $\delta = 77.0$ ppm for ¹³C as internal standard. Data are reported as follows: chemical shift (integration, multiplicity, coupling constants (*J*) and signal assignment). The infrared spectra were carried out using the ATR technique in a NICOLET 6700. Mass spectra with low- and high-resolution systems were recorded using Bruker FTMS APEXIII and VG AutoSpect M mass spectrometers. Melting points were determined on a STUART SMP20 apparatus.

1.2. Materials and Methods (Biological part)

Chemicals. 20aHC (Sigma), 25HC (MedChemExpress), T0901317 (Tocris Biosciences) and Gemini ligands **1**, **3**, **5** and **6** were dissolved in absolute ethanol at 10⁻² M. 20epi-cholesterol and Gemini ligand **4** were dissolved in 80% ethanol 20% DMSO at 10⁻²M. All ligands were stored at -20 °C until use.


Expression and purification. The sequences encoding the His-hROR γ (264-518) was inserted into pET15b expression plasmid. The protein was produced in Escherichia coli BL21 DE3 by induction with 1 mM IPTG at an OD₆₀₀ of ~0.8 and incubation at 22°C for 2h30. Soluble protein was purified by Ni-NTA chromatography followed by size exclusion chromatography on a Superdex 200 (GE) column equilibrated in 20mM Tris-HCl pH7.5, 150mM NaCl, 1mM TCEP. Purity and homogeneity of the hROR γ LBD was assessed by SDS-PAGE. The purified protein was concentrated to 0.7 mg/mL with an Amicon Ultra 10 kDa MWCO. The aliquots of purified LBD are incubated with the 5 equivalent ligands were used for thermal stability experiments or crystallization assays.

Nanoscale Differential Scanning Fluorimetry. Fluorescence based thermal experiments were performed using Prometheus NT.48 (NanoTemper Technologies, Germany) with capillaries containing 10 μ L ROR γ LBD with different ligands. The temperature was increased by a rate of 1 °C/min from 20 to 95 °C and the fluorescence at emission wavelengths of 330 nm and 350 nm was measured for 3 technical replicates. NanoTemper

PR.Stability Analysis v1.0.2 was used to fit the data and to determine the melting temperatures T_m . Presented data is the average of 3 biological replicates except for 25HC that correspond to the average of 3 technical replicates.

Crystallization and structure determination. Crystals were obtained in 0.8M NH_4 acetate, 0.1M Hepes pH = 7.5 at 293K. Protein crystals were mounted in a fiber loop and flash-cooled under a nitrogen flux after cryoprotection with Glycerol 20%. Data collection from a single frozen crystal was performed at 100 K on the ID23-2 at ESRF (France). The raw data were processed with XDS³⁶ and scaled with AIMLESS³⁷ programs. The crystals belong to the space group $P6_1$, with two LBD complexes per asymmetric unit. The structure was solved and refined using Phenix³⁸ and iterative model building using COOT.⁴⁵ Crystallographic refinement statistics are presented in Supplementary Table 1. All structural figures were prepared using PyMOL (www.pymol.org/).

1.2. Synthesis of (3*S*,8*R*,9*S*,10*R*,13*S*,14*S*)-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl 4-methylbenzenesulfonate (**10**)



To a solution of **dehydroepiandrosterone** (360 mg, 1.25 mmol) in pyridine (7 mL) cooled to 0 °C was added *p*-TsCl (608 mg, 1.25 mmol). The ice bath was removed after 5 minutes and stirring was continued at rt for 5 hours. Saturated NaHCO₃ solution (15 mL) was then added and extracted with CH₂Cl₂ (2x30 mL). The combined organic phases were dried with Na₂SO₄, filtered and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 10% EtOAc/hexane), affording compound **10** (470 mg, 86%).

Compound **10**: white solid; R_f: 0.54 (50% EtOAc/hexane).

IR (NaCl, cm⁻¹): 2947, 2581, 2362, 1735, 1534, 1455, 1360.

[α]_D²³ = -10.79 (c 1.18, CHCl₃).


¹H-NMR (CDCl₃, δ): 7.79 (2H, d, *J*=8.3 Hz, Ph), 7.73 (2H, d, *J*=8.0 Hz, Ph), 5.34 (1H, d, *J*=4.7 Hz, H-6), 4.32 (1H, m, H-3), 2.44 (3H, s, CH₃-Ts), 2.43 (2H, m), 2.34 (1H, m), 1.93 (2H, m), 1.80 (5H, m), 1.62 (5H, m), 1.25 (3H, m), 1.02 (2H, m), 0.99 (3H, s, CH₃-18), 0.86 (3H, s, CH₃-19) ppm.

¹³C-NMR (CDCl₃, δ): 220.6 (C-17), 144.5 (C-Ph), 138.9 (C-Ph), 134.4 (C-5), 129.8 (CH-Ph), 127.5 (CH-Ph), 122.8 (CH-6), 81.9 (CH-3), 51.5 (CH), 49.9 (CH), 47.3 (C-13), 38.8 (CH₂), 36.7 (CH₂), 36.4 (C-10), 35.7 (CH₂), 31.3 (CH₂), 31.2 (CH), 30.6 (CH₂), 28.4 (CH₂), 21.7 (CH₂), 21.6 (CH₃), 20.2 (CH₂), 19.1 (CH₃), 13.5 (CH₃) ppm.

MS (ESI⁺) (*m/z*, %): 443.61 (M⁺+1, 2), 272.57 (22), 271.57 (M⁺-TsO, 100), 253.58 (6).

HRMS (ESI⁺): 443.2251 calculated for C₂₆H₃₅O₄S and found 443.2251.

1.3. Synthesis of (1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bR*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyltetradecahydrocyclopenta[*a*]cyclopropano[2,3]cyclopenta[1,2-*f*]naphthalen-6(1*H*)-one (11)



A solution of ketone **10** (403 mg, 0.91 mmol) and pyridine (0.22 mL, 2.73 mmol) in MeOH (6 mL) was heated at 75 °C for 3 hours. Once the mixture reached rt, the solvent was removed in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 5% EtOAc/hexane), affording compound **11** (275 mg, 99%).

Compound **11**: colourless oil; Rf: 0.43 (10% EtOAc/hexane).

IR (NaCl, cm^{-1}): 2930, 2867, 1738, 1469, 1374, 1095, 1014.

$[\alpha]_{\text{D}}^{23} = +81.30$ (c 1.00, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 3.34 (3H, s, MeO), 2.81 (1H, m, H-6), 2.42 (2H, dd, $J=19.1/8.8$ Hz, H-16), 2.15-1.12 (16H, m), 1.03 (3H, s, CH_3 -18), 0.90 (3H, s, CH_3 -19), 0.52 (1H, m, H-4), 0.31 (1H, m, H-4) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 220.6 (C-17), 81.7 (CH-6), 56.5 (CH_3 -OMe), 51.3 (CH), 48.1 (CH), 47.8 (C), 43.4 (C), 35.7 (CH_2), 34.9 (C-5), 34.1 (CH_2), 33.2 (CH_2), 31.7 (CH_2), 30.0 (CH), 24.8 (CH_2), 21.9 (CH_2), 21.6 (CH_2), 21.1 (CH-3), 19.1 (CH_3), 13.8 (CH_3), 13.1 (CH_2 -4) ppm.

MS (ESI⁺) (m/z , %): 303.46 ($\text{M}^+ + 1$, 16), 272.46 ($\text{M}^+ - \text{MeO}$, 100), 253.58 (13).

HRMS (ESI⁺): 303.2319 calculated for $\text{C}_{20}\text{H}_{31}\text{O}_2$ and found 303.2328.

1.4. Synthesis of ethyl (E)-2-((1aR,3aR,3bS,5aS,8aS,8bS,10R,10aR)-10-methoxy-3a,5a-dimethyltetradecahydrocyclopenta[a]cyclopropa[2,3]cyclopenta[1,2-f]naphthalen-6(1H)-ylidene)acetate (**12**)



On a mixture of the ketone **11** (1.43 g, 4.73 mmol) and triethyl phosphonoacetate (4.7 mL, 23.7 mmol) was added a suspension of NaH previously washed with hexane (1.14 g, 47.5 mmol) in EtOH (17 mL). The reaction mixture was heated at 70 °C for 16 hours. A saturated NaCl solution (30 mL) was added and extracted with CH₂Cl₂ (3x50 mL). The combined organic phases were dried with Na₂SO₄, filtered and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 5% EtOAc/hexane), affording compound **12** (1.75 g, 99%).

Compound **12**: colourless oil; R_f: 0.46 (10% EtOAc/hexane).

IR (NaCl, cm⁻¹): 2931, 2868, 1707, 1650, 1453, 1386, 1260, 1037, 859.

[α]_D²³ = +27.35 (c 0.95, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.44 (1H, s, H-20), 4.07 (2H, m, CH₂-OEt), 3.27 (3H, s, MeO), 2.77 (2H, m, H-16), 2.71 (1H, m, H-6), 1.85 (5H, m), 1.54 (5H, m), 1.12 (2H, m), 0.97 (3H, s, CH₃-18), 0.87 (4H, m), 0.79 (3H, s, CH₃-19), 0.58 (1H, dd, J=4.1/4.0 Hz, H-4), 0.37 (1H, dd, J=5.5/7.5 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 176.3 (C-17), 167.3 (C=O), 108.3 (CH-20), 82.0 (CH-6), 59.3 (CH₂-OEt), 56.5 (CH₃-OMe), 53.6 (CH), 48.1 (CH), 46.4 (C), 43.4 (C), 35.5 (CH₂), 35.1 (C-5), 35.0 (CH₂), 33.3 (CH₂), 30.4 (CH₂), 30.2 (CH), 24.8 (CH₂), 24.2 (CH₂), 22.6 (CH₂), 21.3 (CH-3), 19.3 (CH₃), 18.6 (CH₃), 14.3 (CH₃), 13.1 (CH₂-4) ppm.

MS (ESI⁺) (m/z, %): 374.24 (M⁺+2, 23), 373.24 (M⁺+1, 100), 271.27 (M⁺-MeO, 4).

HRMS (ESI⁺): 373.2737 calculated for C₂₄H₃₇O₃ and found 373.2737.

1.5. Synthesis of (*E*)-2-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bS*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyltetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6(1*H*)-ylidene)ethan-1-ol (**13**)



To a solution of the ester **12** (2.12 g, 5.7 mmol) in CH_2Cl_2 (7 mL) cooled to $-78\text{ }^\circ\text{C}$ was added a 1 M solution of DIBAL-H in hexane (17 mL, 17.1 mmol) and the resulting mixture was stirred under these conditions for 2 hours. $t\text{BuOMe}$ (10 mL) and H_2O (3 mL) were added and stirring at rt for 30 minutes. Then Na_2SO_4 was added, vacuum filtered and washed with AcOEt. After evaporation to dryness of the filtered liquids, the residue was purified by silica gel column chromatography (mobile phase: 20% EtOAc/hexane), affording compound **13** (1.83 mg, 99%).

Compound **13**: colourless oil; Rf: 0.49 (30% EtOAc/hexane).

IR (ATR, cm^{-1}): 3394, 2930, 2867, 1675, 1374, 992, 735.

$[\alpha]_{\text{D}}^{24} = +18.37$ (c 1.00, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 5.17 (1H, t, $J=6.7$ Hz, H-20), 4.05 (2H, dd, $J=6.8/12.2$ Hz, H-21), 3.29 (3H, s, MeO), 2.75 (2H, m, H-6), 2.62 (1H, s, OH), 2.31 (2H, m, H-16), 1.91 (2H, m), 1.75 (4H, m), 1.48 (3H, m, $\text{CH}_3\text{-OEt}$), 1.45-1.03 (4H, m), 1.00 (3H, s, $\text{CH}_3\text{-18}$), 0.82 (3H, m), 0.77 (3H, s, $\text{CH}_3\text{-19}$), 0.62 (1H, m, H-4), 0.40 (1H, m, H-4) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 155.2 (C-17), 115.5 (CH-20), 82.3 (CH-6), 60.0 ($\text{CH}_2\text{-21}$), 56.5 (MeO), 54.2 (CH), 48.4 (CH), 44.2 (C), 43.5 (C), 36.1 (CH_2), 35.1 (C-5), 35.1 (CH_2), 33.3 (CH_2), 30.3 (CH), 26.2 (CH_2), 24.9 (CH_2), 24.2 (CH_2), 22.6 (CH_2), 21.4 (CH-3), 19.3 (CH_3), 18.9 (CH_3), 13.1 ($\text{CH}_2\text{-4}$) ppm.

MS (ESI⁺) (m/z , %): 353.24 ($\text{M}^+\text{+Na}^+$, 11), 281.32 (100), 147.34 (44), 145.34 (23).

HRMS (ESI⁺): 353.2451 calculated for $\text{C}_{22}\text{H}_{34}\text{NaO}_2$ and found 353.2446.

1.6. Synthesis of *tert*-butyl((*E*)-2-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bS*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyltetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6(1*H*)-ylidene)ethoxy)dimethylsilane (**14**)



To a solution of allyl alcohol **13** (3.54 g, 10.94 mmol) in CH_2Cl_2 (20 mL), Im (1.5 g, 21.9 mmol), DMAP (cc) and TBSCl (2.15 g, 14.23 mmol) were successively added and the mixture was stirred for 1 hour. H_2O (10 mL) was added and extracted with CH_2Cl_2 (3x30 mL). The combined organic phases were washed with a saturated NaCl solution (2x20 mL), dried with Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 1% EtOAc/hexane), affording compound **14** (4.81 g, 99%).

Compound **14**: colourless oil; Rf: 0.76 (10% EtOAc/hexane).

IR (ATR, cm^{-1}): 2928, 2853, 1679, 1471, 1374, 1253.

$[\alpha]_{\text{D}}^{23} = +32.00$ (c 1.00, CHCl_3).

$^1\text{H-NMR}$ (CDCl_3 , δ): 5.14 (1H, dd, $J=2.4/8.9$ Hz, H-20), 4.16 (2H, m, H-21), 3.34 (3H, s, MeO), 2.79 (1H, t, $J=2.8$ Hz, H-6), 2.41-2.16 (2H, m, H-16), 1.95 (1H, dt, $J=3.0/13.4$ Hz), 1.79 (4H, m), 1.52 (3H, m), 1.50-1.19 (6H, m), 1.13 (1H, m), 1.05 (3H, s, CH_3 -18), 0.98 (1H, m), 0.91 (9H, s, CH_3 -^tBu), 0.81 (3H, s, CH_3 -19), 0.65 (1H, dd, $J=9.3/13.3$ Hz, H-4), 0.44 (1H, dd, $J=11.5/23.1$, H-4), 0.07 (6H, s, CH_3 -Si) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 152.8 (C-17), 116.4 (CH-20), 82.3 (CH-6), 61.3 (CH_2 -21), 56.6 (MeO), 54.2 (CH), 48.4 (CH), 44.1 (C), 43.5 (C), 36.1 (CH_2), 35.2 (C-5), 35.1 (CH_2), 33.4 (CH_2), 30.3 (CH), 26.3 (CH_2), 26.0 (CH_3 -^tBu), 24.9 (CH_2), 24.3 (CH_2), 22.7 (CH_2), 21.4 (CH-3), 19.3 (CH_3), 18.9 (CH_3), 18.4 (C-^tBu), 13.1 (CH_2 -4), -4.8 (CH_3 -Si), -4.9 (CH_3 -Si) ppm.

MS (ESI⁺) (m/z, %): 444.32 (M^+ , 2), 443.33 (M^+-1 , 2), 413.29 (M^+-MeO , 9), 281.32 (100).

HRMS (ESI⁺): 443.3334 calculated for $\text{C}_{28}\text{H}_{47}\text{O}_2\text{Si}$ and found 443.3334.

$[\alpha]_D^{23} = +20.25$ (c 0.75, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 5.35 (1H, m, H-20), 4.86 (1H, m, H-16), 4.37 (1H, dd, $J=5.6/13.4$ Hz, H-21), 4.26 (1H, dd, $J=5.6/13.4$ Hz, H-21), 3.54 (1H, s, OH), 3.38 (3H, s, MeO), 2.82 (1H, m, H-6), 1.99-1.13 (16H, m), 1.05 (3H, s, CH_3 -18), 0.90 (9H, s, CH_3 - ^tBu), 0.83 (3H, s, CH_3 -19), 0.69 (1H, dd, $J=8.2/12.6$ Hz, H-4), 0.47 (1H, dd, $J=5.1/8.0$ Hz, H-4), 0.12 (6H, s, CH_3 -Si) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 159.9 (C-17), 118.6 (CH-20), 82.3 (CH-6), 70.8 (CH-16), 61.1 (CH_2 -21), 56.6 (MeO), 51.3 (CH), 48.3 (CH), 45.2 (C), 43.5 (C), 36.7 (CH_2), 35.1 (C-5), 35.1 (CH_2), 34.6 (CH_2), 33.3 (CH_2), 29.8 (CH), 25.9 (CH_3 - ^tBu), 24.9 (CH_2), 22.7 (CH_2), 21.3 (CH), 20.3 (CH_3), 19.3 (CH_3), 18.3 (C- ^tBu), 13.2 (CH_2 -4), -5.3 (CH_3 -Si), -5.4 (CH_3 -Si) ppm.

MS (ESI $^+$) (m/z, %): 483.34 ($\text{M}^+ + \text{Na}$, 20), 443.37 ($\text{M}^+ - \text{OH}$, 100), 429.35 ($\text{M}^+ - \text{OMe}$, 3)

HRMS (ESI $^+$): 483.3265 calculated for $\text{C}_{28}\text{H}_{48}\text{NaO}_3\text{Si}$ and found 483.3276.

1.8. Synthesis of (1*a*R,3*a*R,3*b*S,5*a*S,7*S*,8*a*S,8*b*R,10*R*,10*a*R,*E*)-6-(2-((*tert*-butyldimethylsilyl)oxy)ethylidene)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-7-ol (**16**)



A solution of the ketone **14** (70 mg, 0.153 mmol) in Et₂O (1.5 mL) was added dropwise to a suspension of LiAlH₄ (58 mg, 1.53 mmol) in Et₂O (2.5 mL) cooled to 0 °C. After the addition was complete, the cold bath was removed and the reaction mixture was stirred at rt for 16 hours. H₂O (5 mL) was added and the aqueous solution was extracted with Et₂O (4x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 25% EtOAc/hexane), affording the allylic alcohol **16** (56 mg, 80%).

Compound **16**: white solid (mp: 129-131 °C); R_f: 0.28 (20% EtOAc/hexane).

IR (ATR, cm⁻¹): 3264, 2925, 2855, 1469, 1058, 834, 775.

[α]_D²⁷ = +63.12 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.57 (1H, m, H-20), 4.42 (2H, m, H-21), 4.34 (1H, m, H-16), 3.37 (3H, s, MeO), 2.82 (1H, m, H-6), 2.23-1.20 (13H, m), 1.11 (3H, s, CH₃-18), 1.10 (3H, m), 0.95 (9H, s, CH₃-^tBu), 0.92 (3H, s, CH₃-19), 0.69 (1H, m, H-4), 0.48 (1H, m, H-4), 0.12 (6H, s, CH₃-Si) ppm.

¹³C-NMR (CDCl₃, δ): 154.6 (C-17), 124.8 (CH-20), 82.2 (CH-6), 75.1 (CH-16), 59.5 (CH₂-21), 56.6 (MeO), 51.4 (CH), 47.9 (CH), 44.2 (C), 43.5 (C), 37.3 (CH₂), 35.1 (C-5), 35.0 (CH₂), 34.4 (CH₂), 33.3 (CH₂), 29.5 (CH), 26.0 (CH₃-^tBu), 24.9 (CH₂), 22.5 (CH₂), 21.4 (CH), 19.2 (CH₃), 18.6 (CH₃), 18.4 (C-^tBu), 13.2 (CH₂-4), -5.02 (CH₃-Si), -5.0 (CH₃-Si) ppm.

MS (ESI⁺) (m/z, %): 483.32 (M⁺+Na, 42), 411.31 (M⁺-49, 15), 279.21 (100).

HRMS (ESI⁺): 483.3265 calculated for C₂₈H₄₈NaO₃Si and found 483.3248.

1.9. Synthesis of methyl (S)-4-((tert-butyl dimethylsilyl)oxy)-3-((1aR,3aR,3bS,5aS,8aS,8bR,10R,10aR)-10-methoxy-3a,5a-dimethyl-1,1a,2,3,3a,3b,4,5,5a,8,8a,8b,9,10-tetradecahydrocyclopenta[a]cyclopropa[2,3]cyclopenta[1,2-f]naphthalen-6-yl)butanoate (**9**)



To a solution of allylic alcohol **17** (480 mg, 1.04 mmol) in $\text{MeC}(\text{OMe})_3$ (10 mL) was added TMBA (cat.) and heated in a sealed tube at $140\text{ }^\circ\text{C}$ for 24 hours. Once the reaction mixture reached rt, the solvent was removed in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 3% EtOAc/hexane), affording the compound **9** (490 mg, 91%).

Compound **9**: colourless oil; Rf: 0.80 (20% EtOAc/hexane).

IR (ATR, cm^{-1}): 2951, 2927, 2853, 1741, 1471, 1435, 1094, 776.

$[\alpha]_D^{25} = +42.50$ (c 0.75, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 5.35 (1H, s, H-16), 3.69 (1H, m, H-21), 3.66 (3H, s, $\text{CH}_3\text{-C=O}$), 3.50 (1H, m, H-21), 3.38 (3H, s, MeO), 2.81 (1H, t, $J=5.2$ Hz, H-6), 2.76 (1H, dd, $J=7.2/12.2$ Hz, H-20), 2.67 (1H, dd, $J=6.4/15.0$ Hz, H-22), 2.41 (1H, dd, $J=7.5/15.1$ Hz, H-22), 2.28 (1H, m), 2.09 (1H, ddd, $J=3.2/6.5/14.9$ Hz), 2.01-1.70 (5H, m), 1.59-1.42 (4H, m), 1.31 (2H, m), 1.15 (1H, td, $J=2.6/13.2$ Hz), 1.07 (3H, s, $\text{CH}_3\text{-18}$), 0.94-0.90 (2H, m), 0.89 (9H, s, $\text{CH}_3\text{-}^t\text{Bu}$), 0.85 (3H, s, $\text{CH}_3\text{-19}$), 0.69 (1H, m, H-4), 0.47 (1H, dd, $J=5.2/7.8$ Hz, H-4), 0.06 (6H, s, $\text{CH}_3\text{-Si}$) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 173.5 (C=O), 155.2 (C-17), 124.2 (CH-16), 82.4 (CH-6), 66.2 ($\text{CH}_2\text{-21}$), 57.1 (CH-14), 56.6 (MeO), 51.2 ($\text{CH}_3\text{-C=O}$), 48.6 (CH), 47.3 (C-10), 43.6 (C-13), 37.2 (CH_2), 37.0 (CH-20), 35.4 (C-5), 35.1 (CH_2), 34.9 (CH_2), 33.1 (CH_2), 31.3 (CH_2), 29.1 (CH), 25.9 ($\text{CH}_3\text{-}^t\text{Bu}$), 24.9 (CH_2), 22.4 (CH_2), 21.4 (CH), 19.2 (CH_3), 18.3 (C- ^tBu), 17.0 (CH_3), 13.1 ($\text{CH}_2\text{-4}$), -5.4 ($\text{CH}_3\text{-Si}$), -5.5 ($\text{CH}_3\text{-Si}$) ppm.

MS (ESI⁺) (m/z, %): 539.37 ($\text{M}^+\text{+Na}$, 80), 517.37 ($\text{M}^+\text{+1}$, 100), 485.33 ($\text{M}^+\text{-OMe}$, 12).


HRMS (ESI⁺): 517.3708 calculated for $\text{C}_{31}\text{H}_{53}\text{O}_4\text{Si}$ and found 517.3700.

1.10. Synthesis of methyl (S)-4-((tert-butyl dimethylsilyl)oxy)-3-((1aR,3aR,3bS,5aS,8aS,8bR,10R,10aR)-10-methoxy-3a,5a-dimethyl-1,1a,2,3,3a,3b,4,5,5a,8,8a,8b,9,10-tetradecahydrocyclopenta[a]cyclopropa[2,3]cyclopenta[1,2-f]naphthalen-6-yl)butanoate (**9**)



To a solution of allylic alcohol **16** (20 mg, 0.04 mmol) in MeC(OMe)₃ (2 mL) was added TMBA (cat.) and heated in a sealed tube at 140 °C for 14 hours. Once the reaction mixture reached rt, the solvent was removed in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 3% EtOAc/hexane), affording the compound **9** (17 mg, 85%), whose physical constants and spectroscopic data virtually coincide with those described for this compound in section 1.9.

1.11. Synthesis of (S)-4-((tert-butyl dimethylsilyl)oxy)-3-((1*a*R,3*a*R,3*b*S,5*a*S,8*a*S,8*b*R,10*R*,10*a*R)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)butan-1-ol (**18**)



To a solution of the ester **9** (1.41 g, 2.73 mmol) in CH_2Cl_2 (3 mL) cooled to $-78\text{ }^\circ\text{C}$ was added a 1 M solution of DIBAL-H in hexane (13.6 mL, 13.6 mmol) and the resulting mixture was stirred under these conditions for 15 hours. $t\text{-BuOMe}$ (10 mL) and H_2O (2 mL) were added and the mixture allowed to reach rt. Stirring was continued till the formation of a white gel before adding H_2O (2 mL) and a 4 M aqueous solution of NaOH (2 mL). Stirring was continued till the formation of a white solid. The solid was separated by filtration. After evaporation to dryness of the filtered liquids, the residue was purified by silica gel column chromatography (mobile phase: 10% EtOAc/hexane), affording the compound **18** (1.03 g, 77%).

Compound **18**: colourless oil; Rf: 0.55 (20% EtOAc/hexane).

IR (ATR, cm^{-1}): 3410, 2998, 2927, 2853, 1471, 1373, 1254, 1088, 737.

$[\alpha]_{\text{D}}^{24} = +49.20$ (c 1.10, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 5.38 (1H, d, $J=1.1$ Hz, H-16), 3.62 (2H, m, H-23), 3.57 (2H, m, H-21), 3.35 (3H, s, MeO), 2.96 (1H, s, OH), 2.79 (1H, t, $J=2.6$ Hz, H-6), 2.39 (1H, s), 2.28-2.25 (2H, m), 2.12-2.04 (2H, m), 1.91 (2H, m), 1.81 (1H, m), 1.73 (2H, m), 1.56-1.47 (4H, m), 1.36-1.28 (3H, m), 1.15 (2H, m), 1.05 (3H, s, CH_3 -18), 0.90 (9H, s, CH_3 - $t\text{Bu}$), 0.81 (3H, s, CH_3 -19), 0.67 (1H, dd, $J=8.5/13.2$ Hz, H-4), 0.45 (1H, dd, $J=5.1/8.0$ Hz, H-4), 0.07 (6H, s, CH_3 -Si) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 156.7 (C-17), 123.2 (CH-16), 82.3 (CH-6), 67.6 (CH_2 -21), 61.6 (CH_2 -23), 56.9 (CH-14), 56.6 (MeO), 48.7 (CH), 47.6 (C-10), 43.6 (C-13), 38.2 (CH), 37.3 (CH_2), 35.3 (C-5), 35.2 (CH_2), 34.9 (CH_2), 33.1 (CH_2), 31.3 (CH_2), 29.1 (CH), 25.9 (CH_3 - $t\text{Bu}$), 24.9 (CH_2), 22.4 (CH_2), 21.3 (CH-3), 19.2 (CH_3 -18), 18.3 (C- $t\text{Bu}$), 16.7 (CH_3 -19), 13.1 (CH_2 -4), -5.4 (CH_3 -Si), -5.4 (CH_3 -Si) ppm.

MS (ESI $^+$) (m/z, %): 489.37 (M^++1 , 100), 457.33 (M^+-OMe , 5).

HRMS (ESI $^+$): 489.3758 calculated for $\text{C}_{30}\text{H}_{53}\text{O}_3\text{Si}$ and found 489.3772.

1.12. Synthesis of (S)-4-((tert-butyl dimethylsilyl)oxy)-3-((1*a*R,3*a*R,3*b*S,5*a*S,8*a*S,8*b*R,10*R*,10*a*R)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)butanal (**19**)



To a solution of alcohol **18** (1.01 g, 2.07 mmol) in CH_2Cl_2 (5 mL) were added 4Å molecular sieves (MS) (600 mg), NMO (726 mg, 6.2 mmol) and TPAP (cat.). The resulting greenish suspension was stirred at rt for 2 h. The solvent was evaporated and the residue was purified by silica gel column chromatography (mobile phase: 10% EtOAc/hexane), affording the compound **19** (540 mg, 54%).

Compound **19**: colourless oil; Rf: 0.75 (20% EtOAc/hexane).

IR (ATR, cm^{-1}): 2951, 2927, 2853, 1726, 1470, 1253, 775.

$[\alpha]_D^{24} = +49.10$ (c 1.00, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 9.69 (1H, s, H-23), 5.44 (1H, s, H-16), 3.72 (1H, dd, $J=4.4/9.8$ Hz, H-21), 3.48 (1H, t, $J=9.6$ Hz, H-21), 3.36 (3H, s, MeO), 2.88-2.78 (2H, m, H-6 y H-20), 2.63 (1H, ddd, $J=2.7/6.9/16.0$ Hz, H-22), 2.46 (1H, ddd, $J=2.1/6.8/16.0$ Hz, H-22), 2.08 (1H, m), 2.00–1.84 (3H, m), 1.84–1.69 (2H, m), 1.60–1.43 (4H, m), 1.41–1.23 (3H, m), 1.14 (1H, td, $J=12.0/15.8$ Hz), 1.05 (3H, s, CH_3 -18), 0.99-0.86 (2H, m), 0.88 (9H, s, CH_3 -*t*Bu), 0.85 (3H, s, CH_3 -19), 0.66 (1H, m, H-4), 0.46 (1H, dd, $J=5.1/7.8$ Hz, H-4), 0.03 (6H, s, CH_3 -Si) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 202.9 (CH-23), 154.7 (C-17), 125.2 (CH-16), 82.3 (CH-6), 66.6 (CH_2 -21), 57.1 (CH-14), 56.7 (MeO), 48.6 (CH), 47.4 (C-10), 47.2 (CH_2), 43.6 (C-13), 35.8 (CH), 35.3 (C-5), 35.1 (CH_2), 35.1 (CH_2), 33.1 (CH_2), 31.3 (CH_2), 29.1 (CH), 25.9 (CH_3 -*t*Bu), 24.9 (CH_2), 22.4 (CH_2), 21.3 (CH-3), 19.2 (CH_3 -18), 18.3 (C-*t*Bu), 17.0 (CH_3 -19), 13.1 (CH_2 -4), -5.4 (CH_3 -Si), -5.5 (CH_3 -Si) ppm.

MS (ESI⁺) (m/z , %): 487.35 (M^++1 , 11), 456.33 (44), 455.39 (M^+-OMe , 100).

HRMS (ESI⁺): 487.3602 calculated for $\text{C}_{30}\text{H}_{51}\text{O}_3\text{Si}$ and found 487.3600.

1.13. Synthesis of ethyl (*S,E*)-6-((*tert*-butyldimethylsilyl)oxy)-5-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bR*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)hex-2-enoate (**35**)



To a solution of aldehyde **19** (516 mg, 1.06 mmol) in THF (10 mL) was added $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Et}$ (740 mg, 2.12 mmol) and the resulting mixture was stirred at rt for 16 hours. The solvent was evaporated and the residue was purified by silica gel column chromatography (mobile phase: 5% EtOAc/hexane), affording the compound **35** (589 mg, 95%).

Compound **35**: colourless oil; Rf: 0.77 (20% EtOAc/hexane).

IR (ATR, cm^{-1}): 2951, 2927, 2852, 1720, 1103, 838.

$[\alpha]_{\text{D}}^{24} = +93.98$ (c 1.00, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 6.92 (1H, m, H-23), 5.78 (1H, d, $J=15.5$ Hz, H-24), 5.38 (1H, s, H-16), 4.18 (2H, q, $J=7.1$ Hz, $\text{CH}_2\text{-OEt}$), 3.59 (1H, dd, $J=9.9/4.3$ Hz, H-21), 3.48 (1H, dd, $J=9.9/8.3$ Hz, H-21), 3.35 (3H, s, MeO), 2.79 (1H, m, H-6), 2.52 (1H, m), 2.33 (2H, m), 2.10 (1H, m), 1.92 (3H, m), 1.73 (2H, m), 1.51 (4H, m), 1.32 (3H, m), 1.28 (3H, t, $J=7.1$ Hz, $\text{CH}_3\text{-OEt}$), 1.18 (1H, m), 1.05 (3H, s, $\text{CH}_3\text{-18}$), 0.89 (9H, s, $\text{CH}_3\text{-}^t\text{Bu}$), 0.87 (2H, m), 0.81 (3H, s, $\text{CH}_3\text{-19}$), 0.66 (1H, dd, $J=5.1/3.7$ Hz, H-4), 0.45 (1H, dd, $J=8.0/5.1$ Hz, H-4), 0.04 (6H, s, $\text{CH}_3\text{-Si}$) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 166.5 (C=O), 154.8 (C-17), 148.2 (CH-23), 124.1 (CH-24), 122.3 (CH-16), 82.3 (CH-6), 66.0 ($\text{CH}_2\text{-21}$), 59.9 ($\text{CH}_2\text{-OEt}$), 56.68 (MeO), 56.6 (CH-14), 48.6 (CH-20), 47.4 (C-10), 43.6 (C-13), 39.4 (CH), 35.3 (C-5), 35.1 (CH_2), 35.0 (CH_2), 34.9 (CH_2), 33.07 (CH_2), 31.3 (CH_2), 29.1 (CH), 25.9 ($\text{CH}_3\text{-}^t\text{Bu}$), 24.8 (CH_2), 22.3 (CH_2), 21.3 (CH-3), 19.2 ($\text{CH}_3\text{-18}$), 18.2 (C- ^tBu), 16.7 ($\text{CH}_3\text{-19}$), 14.2 ($\text{CH}_3\text{-OEt}$), 13.1 ($\text{CH}_2\text{-4}$), -5.4 ($\text{CH}_3\text{-Si}$), -5.5 ($\text{CH}_3\text{-Si}$) ppm.

MS (ESI⁺) (m/z , %): 579.38 ($\text{M}^+\text{+Na}$, 7), 557.40 ($\text{M}^+\text{+1}$, 22), 525.38 ($\text{M}^+\text{-OMe}$, 100).

HRMS (ESI⁺): 557.4021 calculated for $\text{C}_{34}\text{H}_{57}\text{O}_4\text{Si}$ and found 557.4022.

1.15. Synthesis of (*S,E*)-2-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bR*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-6-methylhept-4-ene-1,6-diol (**36**)



To a solution of **31** (306 mg, 0.564 mmol) in THF (3 mL) was added a 1 M solution of TBAF in THF (1.7 mL, 1.7 mmol) and the resulting mixture was stirred at rt for 13 hours. A saturated aqueous solution of NH₄Cl (3 mL) was added and the aqueous solution was extracted with EtOAc (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 50% EtOAc/hexane), affording the compound **36** (240 mg, 99%).

Compound **36**: colourless oil; R_f: 0.10 (30% EtOAc/hexane).

IR (ATR, cm⁻¹): 3373, 2926, 2867, 2847, 1372, 1087, 970.

[α]_D²² = +32.54 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.59 (2H, m, H-23/H-24), 5.42 (1H, m, H-16), 3.58 (2H, d, *J*=6.4 Hz, H-21), 3.33 (3H, s, MeO), 2.78 (1H, m, H-6), 2.35 (2H, m), 2.13 (2H, m), 1.92 (3H, m), 1.73 (2H, m), 1.51 (5H, m), 1.33 (2H, m), 1.28 (6H, s, CH₃-26/CH₃-27), 1.14 (1H, m), 1.04 (3H, s, CH₃-18), 0.86 (9H, s, CH₃-^tBu), 0.86 (2H, m), 0.83 (3H, s, CH₃-19), 0.65 (1H, m, H-4), 0.43 (1H, dd, *J*=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 155.5 (C-17), 139.9 (CH-24), 124.8 (CH), 124.2 (CH), 82.3 (CH-6), 70.6 (C-25), 64.5 (CH₂-21), 57.2 (CH-14), 56.6 (MeO), 48.6 (CH-20), 47.4 (C-10), 43.6 (C-13), 40.3 (CH), 35.3 (C-5), 35.1 (CH₂), 35.0 (CH₂), 34.8 (CH₂), 33.1 (CH₂), 31.3 (CH₂), 29.8 (CH₃-26/CH₃-27), 29.1 (CH), 24.9 (CH₂), 22.3 (CH₂), 21.3 (CH-3), 19.2 (CH₃-18), 16.7 (CH₃-19), 13.1 (CH₂-4) ppm.

MS (ESI⁺) (*m/z*, %): 451.31 (M⁺+Na, 13), 379.29 (M⁺-49, 100).

HRMS (ESI⁺): 451.3183 calculated for C₂₈H₄₄NaO₃ and found 451.3173.

1.16. Synthesis of (2*S*)-2-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bS*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-6-methylheptane-1,6-diol (**32**)



To a suspension of alcohol **36** (76 mg, 0.178 mmol) and Pd/C (5%) (cat.) in hexane (2 mL) was stirred at rt under atmosphere of H₂ for 3 hours. The mixture was then filtered through and the filtered liquids was concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 70% EtOAc/hexane), affording the alcohol **32** (53 mg, 71%).

Compound **32**: colourless oil; Rf: 0.28 (50% EtOAc/hexane).

IR (ATR, cm⁻¹): 3363, 2926, 2859, 2842, 1342, 1008, 943.

[α]_D²⁴ = +17.65 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.71 (1H, dd, *J*=11.0/2.9 Hz, H-21), 3.53 (1H, dd, *J*=11.0/5.3 Hz, H-21), 3.33 (3H, s, MeO), 3.15 (1H, s, OH), 2.78 (1H, s, H-6), 1.83 (2H, m), 1.77 (3H, m), 1.47 (15H, m), 1.12 (6H, s, CH₃-26/CH₃-27), 1.10 (2H, m), 1.02 (3H, s, CH₃-18), 0.89 (2H, m), 0.74 (3H, s, CH₃-19), 0.65 (1H, m, H-4), 0.44 (1H, m, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 82.7 (CH-6), 71.5 (C-25), 63.6 (CH₂-21), 56.8 (MeO), 56.5 (CH-14), 50.5 (CH-17), 48.3 (CH-20), 44.3 (CH₂), 43.7 (C-10), 43.1 (C-13), 42.6 (CH), 40.3 (CH₂), 35.5 (C-5), 35.3 (CH₂), 33.6 (CH₂), 30.8 (CH), 29.9 (CH₃), 29.6 (CH₂), 29.5 (CH₃), 27.8 (CH₂), 25.2 (CH₂), 24.4 (CH₂), 23.1 (CH₂), 21.8 (CH-3), 20.6 (CH₂), 19.5 (CH₃-18), 13.4 (CH₂-4), 12.7 (CH₃-19) ppm.

MS (ESI⁺) (*m/z*, %): 455.35 (M⁺+Na, 18), 415.35 (M⁺-OH, 33), 383.33 (M⁺-49, 100).

HRMS (ESI⁺): 455.3496 calculated for C₂₈H₄₈NaO₃ and found 455.3498.

1.17. Synthesis of (6*S*)-7-iodo-6-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bS*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-2-methylheptan-2-ol (**33**)



To a solution of diol **32** (126 mg, 0.315 mmol) in THF (4 mL) were added sequentially PPh₃ (125 mg, 0.473 mmol) and imidazole (65 mg, 0.945 mmol). After cooling the mixture to 0 °C, I₂ (112 mg, 0.441 mmol) was added and stirring continued at rt for 20 minutes. The reaction was quenched with an aqueous saturated solution of NaHCO₃ (5 mL) and the product extracted with EtOAc (3x10 mL). The combined organic phase was washed with a 10% aqueous solution of Na₂S₂O₃ (10 mL), dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 20% EtOAc/hexane), affording the compound **33** (149 mg, 93%).

Compound **33**: colourless oil; R_f: 0.85 (50% EtOAc/hexane).

IR (ATR, cm⁻¹): 3393, 2986, 2928, 2867, 1457, 947, 721.

[α]_D²² = +7.28 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.43 (1H, dd, *J*=9.9/2.9 Hz, H-21), 3.32 (3H, s, MeO), 3.25 (1H, dd, *J*=9.9/4.2 Hz, H-21), 2.77 (1H, s, H-6), 1.92 (3H, m), 1.71 (4H, m), 1.45 (8H, m), 1.25 (6H, m), 1.22 (6H, s, CH₃-26/27), 1.12 (2H, m), 1.02 (3H, s, CH₃-18), 0.88 (3H, m), 0.77 (3H, s, CH₃-19), 0.65 (1H, dd, *J*=5.1/3.6 Hz, H-4), 0.44 (1H, dd, *J*=8.1/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 82.4 (CH-6), 71.0 (C-25), 56.6 (MeO), 56.3 (CH-14), 53.8 (CH-17), 47.9 (CH-20), 43.8 (CH₂), 43.4 (C-10), 42.6 (C-13), 40.5 (CH), 40.1 (CH₂), 35.2 (C-5), 35.0 (CH₂), 33.4 (CH₂), 32.7 (CH₂), 30.5 (CH), 29.4 (CH₃), 29.3 (CH₃), 27.5 (CH₂), 24.9 (CH₂), 23.9 (CH₂), 22.8 (CH₂), 21.5 (CH-3), 20.5 (CH₂), 19.3 (CH₃-18), 18.2 (CH₂-21), 13.2 (CH₂-4), 13.1 (CH₃-19) ppm.

MS (ESI⁺) (*m/z*, %): 565.25 (M⁺+Na, 5), 511.24 (M⁺-OMe, 12), 493.23 (M⁺-49, 100).

HRMS (ESI⁺): 565.2513 calculated for C₂₈H₄₇INaO₂ and found 565.2519.

1.18. Synthesis of ethyl (5*R*)-9-hydroxy-5-((1*aR*,3*aR*,3*bS*,5*aR*,8*aS*,8*bS*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-9-methyldecanoate (34)



To a suspension of Zn (330 mg, 5.05 mmol) in pyridine (7 mL) was added NiCl₂·6H₂O (240 mg, 1.01 mmol) and ethyl acrylate (0.55 mL, 5.05 mmol) and the resulting mixture was stirred at 65 °C. It was observed that the suspension acquires a reddish-brown colour. After 30 minutes the mixture was cooled to 0 °C and was added a solution of the iodide **33** (186 mg, 0.336 mmol) in pyridine (4 mL) and it was stirred under these conditions for 90 minutes. Once the reaction mixture reaches rt, EtOAc (10 mL) was added and the resulting suspension was filtered over celite. The filtered liquids were washed with a 10% solution of CuSO₄ (3x20 mL), H₂O (2x20 mL) and a saturated solution of NaCl (15 mL). The organic phase was dried with Na₂SO₄, filtered and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 20% EtOAc/hexane), affording the compound **34** (146 mg, 84%).

Compound **34**: colourless oil; R_f: 0.83 (50% EtOAc/hexane).

IR (ATR, cm⁻¹): 3447, 2954, 2931, 2860, 1738, 1251, 1164.

[α]_D²⁴ = +28.19 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 4.12 (2H, q, *J*=7.1 Hz, CH₂-OEt), 3.32 (3H, s, MeO), 2.77 (1H, s, H-6), 2.27 (2H, m, CH₂-2'), 1.91 (3H, m), 1.74 (2H, m), 1.61 (2H, m), 1.42 (15H, m), 1.26 (3H, t, *J*=7.1 Hz, CH₃-OEt), 1.22 (6H, s, CH₃-26/27), 1.12 (4H, m), 1.02 (CH₃-18), 0.85 (4H, m), 0.71 (3H, s, CH₃-19), 0.65 (1H, m, H-4), 0.43 (1H, dd, *J*=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 173.9 (C=O), 82.4 (CH-6), 71.0 (C-25), 60.2 (CH₂-2'), 56.5 (MeO), 56.5 (CH-14), 52.5 (CH-17), 48.0 (CH-20), 44.4 (CH₂), 43.4 (C-10), 42.8 (C-13), 40.0 (CH₂), 39.0 (CH), 35.3 (C-5), 35.0 (CH₂), 34.8 (CH₂), 33.3 (CH₂), 31.0 (CH₂), 30.5 (CH), 30.3 (CH₂), 29.3 (CH₃), 29.3 (CH₃), 27.8 (CH₂), 25.0 (CH₂), 24.1 (CH₂), 22.8 (CH₂), 21.5 (CH-3), 21.0 (CH₂), 19.8 (CH₂), 19.3 (CH₃-18), 14.3 (CH₃-OEt), 13.1 (CH₂-4), 12.3 (CH₃-19) ppm.

MS (ESI⁺) (*m/z*, %): 539.40 (M⁺+Na, 35), (M⁺-49, 100).

HRMS (ESI⁺): 539.4071 calculated for C₃₃H₅₆NaO₄ and found 539.4080.

1.19. Synthesis of 6-((1*aR*,3*aR*,3*bS*,5*aR*,8*aS*,8*bS*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-2,10-dimethylundecane-2,10-diol (**37**)



To a solution of compound **34** (118 mg, 0.228 mmol) in THF (2 mL) cooled to $-78\text{ }^{\circ}\text{C}$ was added a 1.5 M solution of MeLi·LiBr in Et₂O (0.76 mL, 1.14 mmol) and the resulting mixture was stirred in these conditions for 2 hours. H₂O (10 mL) was added and the aqueous solution was extracted with CH₂Cl₂ (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 50% EtOAc/hexane), affording the diol **37** (93 mg, 82%).

Compound **37**: colourless oil; R_f: 0.45 (50% EtOAc/hexane).

IR (ATR, cm⁻¹): 3427, 2964, 2931, 2874, 1387, 835, 774.

[α]_D²⁴ = +18.72 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.33 (3H, s, MeO), 2.77 (1H, s, H-6), 1.91 (3H, m), 1.74 (3H, m), 1.42 (18H, m), 1.21 (12H, s, CH₃-26/27/4'/5'), 1.07 (3H, m), 1.03 (3H, s, CH₃-18), 0.88 (4H, m), 0.72 (3H, s, CH₃-19), 0.65 (1H, m, H-4), 0.43 (1H, dd, *J*=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 82.4 (CH-6), 71.1 (C-25/C-3'), 56.5 (MeO), 56.5 (CH-14), 52.7 (CH-17), 48.0 (CH-20), 44.5 (CH₂), 44.4 (CH₂), 43.9 (C-10), 42.8 (C-13), 40.0 (CH₂), 39.1 (CH), 35.3 (C-5), 35.1 (CH₂), 33.3 (CH₂), 31.5 (CH₂), 31.2 (CH₂), 30.5 (CH), 29.3 (CH₃), 29.3 (CH₃), 29.2 (CH₃), 29.2 (CH₃), 27.9 (CH₂), 25.0 (CH₂), 24.1 (CH₂), 22.8 (CH₂), 21.5 (CH-3), 20.2 (CH₂), 19.7 (CH₂), 19.3 (CH₃-18), 13.1 (CH₂-4), 12.7 (CH₃-19) ppm.

MS (ESI⁺) (m/z, %): 525.42 (M⁺+Na, 83), 472.42 (M⁺-MeO, 6), 453.41 (M⁺-49, 68), 435.39 (M⁺-67, 100).

HRMS (ESI⁺): 525.4278 calculated for C₃₃H₅₈NaO₃ and found 525.4285.

1.20. Synthesis of 6-((3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl)-2,10-dimethylundecane-2,10-diol (**3**)



To a solution of diol **37** (51 mg, 0.101 mmol) in dioxane (2 mL) and H₂O (0.5 mL) was added *p*-TsOH (cat.) and the resulting mixture was stirred at 80 °C for 3 hours. H₂O (5 mL) was added and the aqueous solution was extracted with CH₂Cl₂ (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 70% EtOAc/hexane), affording the triol **3** (48 mg, 99%).

Compound **3**: white solid (mp: 197-199 °C); R_f: 0.26 (50% EtOAc/hexane).

IR (ATR, cm⁻¹): 3294, 2961, 2938, 2897, 2882, 1371, 1064, 908.

[α]_D²⁰ = +6.40 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.37 (1H, s, H-6), 3.54 (1H, m, H-3), 2.30 (3H, m), 1.98 (3H, m), 1.85 (3H, m), 1.46 (19H, m), 1.24 (12H, s, CH₃-26/27/4'/5'), 1.09 (3H, m), 1.03 (3H, s, CH₃-18), 0.95 (3H, m), 0.70 (3H, s, CH₃-19) ppm.

¹³C-NMR (CDCl₃, δ): 140.7 (C-5), 121.6 (C-6), 71.7 (CH-3), 71.0 (C-25/C-3'), 56.7 (CH-14), 52.4 (CH-17), 50.1 (CH-20), 44.5 (CH₂), 44.4 (CH₂), 42.3 (CH₂), 42.2 (C-13), 39.4 (CH₂), 39.1 (CH), 37.2 (CH₂), 36.5 (C-10), 31.9 (CH), 31.9 (CH₂), 31.6 (CH₂), 31.4 (CH₂), 31.1 (CH₂), 29.3 (CH₃), 29.3 (CH₃), 29.2 (CH₃), 27.7 (CH₂), 24.1 (CH₂), 21.1 (CH₂), 20.1 (CH₂), 19.7 (CH₂), 19.3 (CH₃-18), 11.9 (CH₃-19) ppm.

MS (ESI⁺) (m/z, %): 511.41 (M⁺+Na, 33), 453.40 (13), 394.43 (100).

HRMS (ESI⁺): 511.4122 calculated for C₃₂H₅₆NaO₃ and found 511.4127.

1.21. Synthesis of iodo(isobutyl)triphenyl- λ^5 -phosphane (**38**)



To a solution of **1-iodo-2-methylpropane** (3.1 g, 16.85 mmol) in CH₃CN (15 mL) was added PPh₃ (6.63 g, 25.31 mmol) and the resulting mixture was stirred at 80 °C for 22 hours. Then it was allowed to reach rt and the solvent was removed by vacuum distillation. The residue was purified by silica gel column chromatography (mobile phase: 5% MeOH/CH₂Cl₂), affording the compound **38** (6.05 g, 80%).

Compound **38**: white solid (mp: 176-180 °C); Rf: 0.10 (2% MeOH/CH₂Cl₂).

IR (ATR, cm⁻¹): 2959, 2867, 1586, 1482, 1435, 1316, 744.


¹H-NMR (CDCl₃, δ): 7.75 (15H, m, Ph), 3.35 (2H, m, CH₂), 2.10 (1H, m, CH), 1.04 (6H, s, CH₃) ppm.

¹³C-NMR (CDCl₃, δ): 135.2 (CH-Ph), 133.7 (CH-Ph), 130.7 (CH-Ph), 118.9 (C-Ph), 31.0 (CH₂), 24.6 (CH), 24.5 (CH₃), 24.4(CH₃) ppm.

MS (ESI⁺) (m/z, %): 321.16 (M⁺+2, 2), 320.16 (M⁺+1, 22), 319.16 (M⁺, 100).

HRMS (ESI⁺): 319.1610 calculated for C₂₂H₂₄P and found 319.1605.

1.22. Synthesis of *tert*-butyl(((*S,E*)-2-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bR*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-6-methylhept-4-en-1-yl)oxy)dimethylsilane (**39**)



To a suspension of phosphonium salt **38** (1.58 g, 3.55 mmol) in THF (5 mL) cooled to 0 ° C was added a 2.5 M solution of *n*-BuLi in hexane (1.33 mL, 3.3 mmol), observing that the mixture of reaction turns orange. After 30 minutes, a solution of the aldehyde **19** (540 mg, 1.11 mmol) in THF (5 mL) was added and the resulting mixture was stirred at rt for 13 hours. A saturated aqueous solution of NH₄Cl (3 mL) was added and the aqueous solution was extracted with EtOAc (2x10 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 2% EtOAc/hexane), affording the alkene **39** (410 mg, 72%).

Compound **39**: colourless liquid; Rf: 0.88 (20% EtOAc/hexane).

IR (ATR, cm⁻¹): 3853, 3743, 2955, 2928, 2854, 1987, 1967, 1457, 837.

[α]_D²² = +48.30 (c 0.65, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.36 (2H, m, CH-16/CH-24), 5.23 (1H, dd, *J*=5.7/10.9 Hz, CH-23), 3.58 (1H, dd, *J*=5.1/9.8 Hz, H-21), 3.51 (1H, dd, *J*=7.8/15.9 Hz, H-21), 3.37 (3H, s, MeO), 2.82 (1H, m, H-6), 2.61 (1H, dd, *J*= 7.4/14.1 Hz), 2.38 (1H, m), 2.28-2.02 (4H, m), 2.01–1.83 (3H, m), 1.83–1.59 (3H, m), 1.59–1.42 (2H, m), 1.41–1.25 (3H, m), 1.23–1.12 (1H, m), 1.04 (3H, s, CH₃-18), 1.01 (2H, m), 0.98 (3H, d, *J*=1.2 Hz, CH₃), 0.96 (3H, d, *J*=1.3 Hz, CH₃), 0.91 (9H, s, CH₃-*t*Bu), 0.79 (3H, s, CH₃-19), 0.66 (1H, m, H-4), 0.47 (1H, dd, *J*=5.1/8.0 Hz, H-4), 0.05 (6H, s, CH₃-Si) ppm.

¹³C-NMR (CDCl₃, δ): 155.9 (C-17), 138.2 (CH-24), 125.5 (CH-16), 123.1 (CH-23), 82.4 (CH-6), 66.3 (CH₂-21), 56.8 (CH-14), 56.7 (MeO), 48.7 (CH), 47.4 (C-10), 43.6 (C-13), 40.3 (CH), 35.4 (C-5), 35.2 (CH₂), 35.0 (CH₂), 33.1 (CH₂), 31.4 (CH₂), 29.8 (CH₂), 29.1 (CH), 26.5 (CH-25), 26.0 (CH₃-*t*Bu), 24.9 (CH₂), 23.2 (CH₃-26/27), 22.4 (CH₂), 21.4 (CH-3), 19.3 (CH₃-18), 18.3 (C-*t*Bu), 16.8 (CH₃-19), 13.1 (CH₂-4), -5.3 (CH₃-Si), -5.3 (CH₃-Si) ppm.

MS (ESI⁺) (*m/z*, %): 527.42 (M⁺+1, 11), 495 (M⁺-MeO, 100).

HRMS (ESI⁺): 527.4279 calculated for C₃₄H₅₈O₂Si and found 527.4274.

1.23. Synthesis of (*S,E*)-2-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bR*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-6-methylhept-4-en-1-ol (**7**)



To a solution of alkene **39** (410 mg, 0.779 mmol) in THF (5 mL) was added a 1 M solution of TBAF in THF (2.5 mL, 2.34 mmol) and the resulting mixture was stirred at rt for 13 hours. A saturated aqueous solution of NH₄Cl (3 mL) was added and the aqueous solution was extracted with EtOAc (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 10% EtOAc/hexane), affording the compound **7** (321 mg, 99%).

Compound **7**: colourless liquid; R_f: 0.50 (20% EtOAc/hexane).

IR (ATR, cm⁻¹): 3479, 2954, 2926, 2852, 1460, 1376, 1095, 812.

[α]_D²² = +7.07 (c 0.40, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.48-5.15 (3H, m, CH-16/23/24), 3.58 (2H, d, *J*=6.1 Hz, H-21), 3.37 (3H, s, MeO), 2.78 (1H, m, H-6), 2.55 (1H, dd, *J*=7.4/14.3 Hz, H-22), 2.31-1.12 (17H, m), 1.04 (3H, s, CH₃-18), 1.03–0.90 (9H, m), 0.88 (3H, s, CH₃-19), 0.65 (1H, m, H-4), 0.44 (1H, dd, *J*=5.1/8.0 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 155.9 (C-17), 138.9 (CH-24), 124.9 (CH-16), 124.1 (CH-23), 82.3 (CH-6), 64.9 (CH₂-21), 57.3 (CH-14), 56.7 (MeO), 48.7 (CH), 47.4 (C-10), 43.6 (C-13), 40.7 (CH), 35.4 (C-5), 35.2 (CH₂), 35.0 (CH₂), 33.1 (CH₂), 31.3 (CH₂), 30.2 (CH₂), 29.2 (CH), 26.6 (CH-25), 24.9 (CH₂), 23.1 (CH₃-26/27), 23.1 (CH₃-26/27), 22.4 (CH₂), 21.4 (CH-3), 19.3 (CH₃-18), 16.8 (CH₃-19), 13.1 (CH₂-4) ppm.

MS (ESI⁺) (*m/z*, %): 413.34 (M⁺+1, 13), 381.33 (M⁺-MeO, 100).

HRMS (ESI⁺): 413.3414 calculated for C₂₈H₄₅O₂ and found 413.3412.

1.24. Synthesis of (S,E)-2-((1aR,3aR,3bS,5aS,8aS,8bR,10R,10aR)-10-methoxy-3a,5a-dimethyl-1,1a,2,3,3a,3b,4,5,5a,8,8a,8b,9,10-tetradecahydrocyclopenta[a]cyclopropa[2,3]cyclopenta[1,2-f]naphthalen-6-yl)-6-methylhept-4-enal (**20**)



To a solution of alcohol **7** (85 mg, 0.206 mmol) in CH₂Cl₂ (3 mL) was added BAIB (100 mg, 0.31 mmol) and TEMPO (cat.) and the resulting mixture was stirred at rt for 3 hours. The solvent was rotatory evaporated to afford a residue which was taken up in ^tBuOMe. The resulting solution was washed with 15% aqueous Na₂S₂O₃ (2 x10 mL) then with a saturated aqueous solution of NaHCO₃ (2x10 mL). The organic phase was dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 5% EtOAc/hexane), affording the compound **20** (65 mg, 78%).

Compound **20**: colourless liquid; R_f: 0.85 (20% EtOAc/hexane).

IR (ATR, cm⁻¹): 2953, 2926, 2871, 1737, 1521, 1281, 777.

[α]²¹_D = +8.32 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 9.43 (1H, s, H-21), 5.55 (1H, m, H-16), 5.22 (2H, m, H-23/24), 3.36 (3H, s, MeO), 2.97 (1H, m, H-20), 2.81 (1H, s, H-6), 2.53 (2H, m), 2.28 (2H, m), 1.95 (3H, m), 1.75 (2H, m), 1.54 (3H, m), 1.30 (3H, m), 1.06 (3H, s, CH₃-18), 0.95 (3H, s, CH₃-26/27), 0.93 (3H, s, CH₃-26/27), 0.87 (3H, m), 0.82 (3H, s, CH₃-19), 0.68 (1H, m, H-4), 0.47 (1H, dd, J=8.0/5.0 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 200.1 (CH-21), 150.1 (C-17), 139.2 (CH-24), 127.7 (CH), 123.4 (CH), 82.1 (CH-6), 56.7 (CH), 56.6 (MeO), 51.9 (CH), 48.5 (CH), 47.3 (C-10), 43.5 (C-13), 35.2 (C-5), 35.1 (CH₂), 34.6 (CH₂), 33.0 (CH₂), 31.5 (CH₂), 29.0 (CH), 27.4 (CH₂), 26.5 (CH-25), 24.8 (CH₂), 22.9 (CH₃-26/27), 22.8 (CH₂), 22.2 (CH₃-26/27), 21.2 (CH-3), 19.1 (CH₃-18), 16.3 (CH₃-19), 13.0 (CH₂-4) ppm.

MS (ESI⁺) (m/z, %): 433.31 (M⁺+Na, 4), 411.32 (M⁺+1, 10), 379.30 (M⁺-MeO, 100).

HRMS (ESI⁺): 411.3258 calculated for C₂₈H₄₃O₂ and found 411.3262.

1.25. Synthesis of bromo(isobutyl)triphenyl- λ^5 -phosphane (**40**)



To a solution of **1-bromo-2-methylpropane** (3.78 g, 25.04 mmol) in CH_3CN (20 mL) was added PPh_3 (9.85 g, 37.6 mmol) and the resulting mixture was stirred at 80 °C for 24 hours. Then it was allowed to reach rt and the solvent was removed by vacuum distillation. The residue was purified by silica gel column chromatography (mobile phase: 15% $\text{MeOH}/\text{CH}_2\text{Cl}_2$), affording the compound **40** (6.59 g, 64%).

Compound **40**: white solid (mp: 114-117 °C); Rf: 0.10 (5% $\text{MeOH}/\text{CH}_2\text{Cl}_2$).

IR (ATR, cm^{-1}): 3478, 3411, 2962, 2910, 2876, 1438, 1109, 995, 756.


$^1\text{H-NMR}$ (CDCl_3 , δ): 7.78 (15H, m, Ph), 3.63 (2H, m, $\text{CH}_2\text{-P}$), 1.96 (1H, m, CH), 1.49 (2H, m, CH_2), 0.98 (6H, s, CH_3) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 135.1 (CH-Ph), 133.7 (CH-Ph), 130.6 (CH-Ph), 118.7 (C-Ph), 31.1 ($\text{CH}_2\text{-P}$), 28.9 (CH), 22.19 (CH_3), 21.4 (CH_2) ppm.

MS (ESI⁺) (m/z , %): 335.17 ($\text{M}^+ + 2$, 3), 334.17 ($\text{M}^+ + 1$, 28), 333.17 (M^+ , 100).

HRMS (ESI⁺): 333.1767 calculated for $\text{C}_{23}\text{H}_{26}\text{P}$ and found 333.1765.

1.26. Synthesis of (1*a*R,3*a*R,3*b*S,5*a*S,8*a*S,8*b*R,10*R*,10*a*R)-6-((*R*,3*E*,7*E*)-2,10-dimethylundeca-3,7-dien-6-yl)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalene (**41**)



To a suspension of phosphonium salt **40** (180 mg, 0.43 mmol) in THF (2 mL) cooled to 0 °C was added a 2.5 M solution of *n*-BuLi in hexane (0.16 mL, 0.4 mmol), observing that the mixture of reaction turns orange. After 30 minutes, a solution of the aldehyde **20** (55 mg, 0.134 mmol) in THF (2 mL) was added and the resulting mixture was stirred at rt for 1 hour. A saturated aqueous solution of NH₄Cl (3 mL) was added and the aqueous solution was extracted with EtOAc (3x12 mL). The combined organic phases were washed with H₂O (20 mL) and a saturated NaCl solution (30 mL), dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 1% EtOAc/hexane), affording the alkene **41** (39 mg, 63%).

Compound **41**: colourless liquid; R_f: 0.95 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 2954, 2923, 2850, 1463, 1375, 1095, 966.

[α]_D²³ = -7.26 (c 0.5, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.43 (1H, s, H-16), 5.34 (2H, m, H-23/24/21/1'), 5.22 (2H, m, H-23/24/21/1'), 3.38 (3H, s, MeO), 3.06 (1H, m, H-20), 2.82 (1H, s, H-6), 2.59 (1H, m), 2.31 (1H, m), 2.10 (2H, m), 1.96 (5H, m), 1.79 (2H, m), 1.58 (6H, m), 1.37 (3H, m), 1.18 (2H, m), 1.09 (3H, s, CH₃-18), 0.95 (6H, d, CH₃-26/27), 0.93 (6H, s, CH₃-4'/5'), 0.86 (3H, s, CH₃-19), 0.69 (1H, t, *J*=4.5 Hz, H-4), 0.48 (1H, dd, *J*=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 158.6 (C-17), 138.0 (CH-24), 134.6 (CH), 127.2 (CH), 125.7 (CH), 122.3 (CH), 82.4 (CH-6), 57.4 (CH), 56.6 (MeO), 48.7 (CH), 47.4 (C-10), 43.6 (C-13), 36.7 (CH₂), 36.6 (CH), 35.5 (C-5), 35.4 (CH₂), 35.1 (CH₂), 33.2 (CH₂), 33.2 (CH₂), 31.2 (CH₂), 29.0 (CH), 28.7 (CH), 26.6 (CH-25), 25.0 (CH₂), 23.2 (CH₃-26/27), 23.2 (CH₃-26/27), 22.6 (CH₃-4'/5'), 22.5 (CH₃-4'/5'), 22.4 (CH₂), 21.5 (CH), 19.3 (CH₃-18), 17.0 (CH₃-19), 13.1 (CH₂-4) ppm.

MS (ESI⁺) (*m/z*, %): 463.39 (M⁺-H, 3), 433.38 (M⁺-MeO, 100).

HRMS (ESI⁺): 463.3934 calculated for C₃₃H₅₁O and found 463.3930.

1.27. Synthesis of (1a*R*,3a*R*,3b*S*,5a*R*,8a*S*,8b*S*,10*R*,10a*R*)-6-(2,10-dimethylundecan-6-yl)-10-methoxy-3a,5a-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalene (**21**)



To a suspension of alkene **41** (38 mg, 0.081 mmol) and Pd/C (10%) (cat.) in EtOAc (3 mL) was stirred at rt under atmosphere of H₂ for 14 hours. The mixture was then filtered through and the filtered liquids was concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 1% EtOAc/hexane), affording the compound **21** (35 mg, 93%).

Compound **21**: colourless liquid; R_f: 0.95 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 2953, 2924, 2853, 1464, 1379, 1099, 966.

[α]_D²² = +4.02 (c 0.5, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.34 (3H, s, MeO), 2.79 (1H, m, H-6), 1.94 (2H, m), 1.77 (3H, m), 1.55 (6H, m), 1.44 (3H, m), 1.32 (6H, m), 1.05 (3H, s, CH₃-18), 0.90 (6H, s, CH₃-26/27), 0.88 (6H, s, CH₃-4'/5'), 0.87 (4H, m), 0.67 (1H, dd, *J*=5.1/3.7 Hz, H-4), 0.45 (1H, dd, *J*=8.0/5.0 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 82.5 (CH-6), 56.5 (MeO), 52.8 (CH), 48.1 (CH), 43.4 (C-10), 42.8 (C-13), 40.0 (CH₂), 39.7 (CH₂), 39.6 (CH₂), 39.3 (CH), 35.4 (C-5), 35.1 (CH₂), 33.4 (CH₂), 31.1 (CH₂), 31.0 (CH₂), 30.5 (CH), 28.0 (CH), 27.9 (CH), 27.8 (CH₂), 25.0 (CH₂), 24.1 (CH₂), 23.2 (CH₂), 22.9 (CH₂), 22.8 (CH₂), 22.8 (CH₃-26/27/4'/5'), 22.7 (CH₃-26/27/4'/5'), 22.7 (CH₃-26/27/4'/5'), 22.6 (CH₃-26/27/4'/5'), 21.6 (CH), 19.3 (CH₃-18), 13.1 (CH₂-4), 12.4 (CH₃-19) ppm.

MS (ESI⁺) (*m/z*, %): 439.43 (M⁺-MeO, 100), 437.41 (25).

HRMS (ESI⁺): 439.4298 calculated for C₃₂H₅₅ and found 439.4296.

1.28. Synthesis of (3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-17-(2,10-dimethylundecan-6-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (1)



To a solution of compound **21** (34 mg, 0.072 mmol) in dioxane (2 mL) and H₂O (0.5 mL) was added *p*-TsOH (cat.) and the resulting mixture was stirred at 80 °C for 3 hours. H₂O (5 mL) was added and the aqueous solution was extracted with CH₂Cl₂ (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 20% EtOAc/hexane), affording the alcohol **1** (32 mg, 99%).

Compound **1**: colourless liquid; R_f: 0.18 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 3360, 2955, 2921, 2850, 1462, 1377, 1187, 969.

[α]_D²³ = -23.43 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.38 (1H, s, H-6), 3.55 (1H, m, H-3), 2.25 (2H, m), 1.97 (2H, m), 1.85 (2H, m), 1.79 (1H, m), 1.72-1.07 (25H, m), 1.03 (3H, s, CH₃-18), 0.95 (3H, m), 0.90 (6H, s, CH₃-26/27/4'/5'), 0.88 (6H, s, CH₃-26/27/4'/5'), 0.69 (3H, s, CH₃-19) ppm.

¹³C-NMR (CDCl₃, δ): 140.8 (C-5), 121.7 (CH-6), 71.8 (CH-3), 56.8 (CH), 52.7 (CH), 50.2 (CH), 42.4 (C-10), 42.3 (CH₂), 39.7 (CH₂), 39.6 (CH₂), 39.5 (CH₂), 39.3 (CH), 37.3 (CH₂), 36.5 (C-13), 32.0 (CH), 31.9 (CH₂), 31.7 (CH₂), 31.1 (CH₂), 31.0 (CH₂), 28.0 (CH), 27.9 (CH), 27.8 (CH₂), 24.2 (CH₂), 23.2 (CH₂), 22.9 (CH₂), 22.8 (CH₃-26/27/4'/5'), 22.7 (CH₃-26/27/4'/5'), 22.7 (CH₃-26/27/4'/5'), 22.6 (CH₃-26/27/4'/5'), 21.2 (CH₂), 19.4 (CH₃-18), 12.0 (CH₃-19) ppm.

MS (ESI⁺) (m/z, %): 439.43 (M⁺-OH, 100).

HRMS (ESI⁺): 439.4298 calculated for C₃₂H₅₅ and found 439.4294.

1.29. Synthesis of ethyl (*R,2E,6E*)-4-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bR*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-8-methylnona-2,6-dienoate (**25**)



To a solution of aldehyde **20** (82 mg, 0.2 mmol) in THF (3 mL) was added $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Et}$ (140 mg, 0.4 mmol) and the resulting mixture was stirred at rt for 19 hours. The solvent was evaporated and the residue was purified by silica gel column chromatography (mobile phase: 3% EtOAc/hexane), affording the ester **25** (78 mg, 82%).

Compound **25**: colourless liquid; Rf: 0.82 (20% EtOAc/hexane).

IR (ATR, cm^{-1}): 2955, 2923, 2851, 1722, 1462, 1374, 1262, 1161, 1107, 967.

$[\alpha]_D^{20} = +8.12$ (c 1.00, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 6.87 (1H, dd, $J=5.6/8.9$ Hz, H-21), 5.78 (1H, dd, $J=15.6/1$ Hz, H-1'), 5.48 (1H, s, H-16), 5.23 (2H, m, H-23/24), 4.19 (2H, q, $J=6$ Hz, $\text{CH}_2\text{-OEt}$), 3.36 (3H, s, MeO), 2.88 (1H, m, H-20), 2.81 (1H, s, H-6), 2.56 (1H, m), 2.30 (2H, m), 2.11 (1H, m), 1.92 (3H, m), 1.73 (2H, m), 1.54 (4H, m), 1.38 (2H, m), 1.30 (3H, 3H, t, $J=7.1$ Hz, $\text{CH}_3\text{-OEt}$), 1.14 (1H, m), 1.06 (3H, s, $\text{CH}_3\text{-18}$), 0.95 (3H, d, $J=3.4$ Hz, $\text{CH}_3\text{-26/27}$), 0.93 (3H, d, $J=3.5$ Hz, $\text{CH}_3\text{-26/27}$), 0.91 (3H, m), 0.82 (3H, s, $\text{CH}_3\text{-19}$), 0.68 (1H, dd, $J=5.1/3.7$ Hz, H-4), 0.47 (1H, dd, $J=8.1/5.1$ Hz, H-4) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 166.7 (C=O), 155.6 (C-17), 152.0 (CH-21), 138.9 (CH-16), 124.5 (CH), 124.3 (CH), 120.2 (CH-1'), 82.3 (CH-6), 60.2 ($\text{CH}_2\text{-OEt}$), 57.2 (CH), 56.7 (MeO), 48.6 (CH), 47.6 (C-10), 43.6 (C-13), 41.6 (CH_2), 35.4 (C-5), 35.1 (CH_2), 35.0 (CH_2), 33.1 (CH_2), 32.2 (CH_2), 31.3 (CH_2), 29.0 (CH), 26.7 (CH-25), 24.9 (CH_2), 23.1 ($\text{CH}_3\text{-26/27}$), 23.0 ($\text{CH}_3\text{-26/27}$), 22.3 (CH_2), 21.4 (CH), 19.2 ($\text{CH}_3\text{-18}$), 16.8 ($\text{CH}_3\text{-19}$), 14.3 ($\text{CH}_3\text{-OEt}$), 13.1 ($\text{CH}_2\text{-4}$) ppm.

MS (ESI⁺) (m/z , %): 503.35 ($\text{M}^+\text{+Na}$, 40), 449.34 ($\text{M}^+\text{-OMe}$, 100).

HRMS (ESI⁺): 503.3496 calculated for $\text{C}_{32}\text{H}_{48}\text{NaO}_3$ and found 503.3485.

1.30. Synthesis of (*R,2E,6E*)-4-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bR*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-8-methylnona-2,6-dien-1-ol (**26**)



To a solution of the ester **25** (78 mg, 0.16 mmol) in CH_2Cl_2 (3 mL) cooled to $-78\text{ }^\circ\text{C}$ was added a 1 M solution of DIBAL-H in hexane (0.65 mL, 0.65 mmol) and the resulting mixture was stirred under these conditions for 22 hours. $t\text{-BuOMe}$ (1 mL) and H_2O (0.5 mL) were added and the mixture allowed to reach rt. Stirring was continued till the formation of a white gel before adding H_2O (0.5 mL) and a 4 M aqueous solution of NaOH (0.5 mL). Stirring was continued till the formation of a white solid. The solid was separated by filtration. After evaporation to dryness of the filtered liquids, the residue was purified by silica gel column chromatography (mobile phase: 20% EtOAc/hexane), affording alcohol **26** (52 mg, 74%)

Compound **26**: colourless liquid; Rf: 0.23 (20% EtOAc/hexane).

IR (ATR, cm^{-1}): 3072, 2956, 2922, 2853, 1462, 1377, 1187, 1080, 965.

$[\alpha]_{\text{D}}^{20} = +12.35$ (c 1.00, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 5.62 (2H, dd, $J=4.8/2.0$ Hz, H-21/1'), 5.42 (1H, s, H-16), 5.21 (2H, m, H-23/24), 4.12 (2H, s, H-2'), 3.37 (3H, s, MeO), 2.81 (1H, s, H-6), 2.76 (1H, m, H-20), 2.57 (1H, m), 2.31 (1H, m), 2.10 (2H, m), 1.95 (4H, m), 1.77 (3H, m), 1.54 (5H, m), 1.35 (2H, m), 1.17 (1H, m), 1.07 (3H, s, CH_3 -18), 0.96 (3H, s, CH_3 -26/27), 0.94 (3H, s, CH_3 -26/27), 0.89 (3H, m), 0.84 (3H, s, CH_3 -19), 0.68 (1H, t, $J=4.3$ Hz, H-4), 0.47 (1H, dd, $J=8.0/5.0$ Hz, H-4) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 157.4 (C-17), 138.2 (CH), 136.7 (CH), 128.1 (CH), 125.3 (CH), 123.0 (CH), 82.4 (CH-6), 63.7 (CH_2 -2'), 57.4 (CH), 56.7 (MeO), 48.7 (CH), 47.5 (C-10), 43.6 (C-13), 41.7 (CH_2), 35.4 (C-5), 35.2 (CH_2), 33.1 (CH_2), 32.7 (CH_2), 31.2 (CH_2), 29.0 (CH), 26.7 (CH), 24.9 (CH_2), 23.1 (CH_3 -26/27), 23.1 (CH_3 -26/27), 22.4 (CH_2), 21.4 (CH), 19.3 (CH_3 -18), 17.0 (CH_3 -19), 13.1 (CH_2 -4) ppm.

MS (ESI $^+$) (m/z, %): 407.33 (M^+ -OMe, 83).

HRMS (ESI $^+$): 407.3308 calculated for $\text{C}_{29}\text{H}_{43}\text{O}$ and found 407.3305.

1.31. Synthesis of (*R,2E,6E*)-4-((1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bR*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-8-methylnona-2,6-dien-1-yl acetate (**27**)



To a solution of allylic alcohol **26** (52 mg, 0.118 mmol) in CH₂Cl₂ (2 mL) was added pyridine (29 μL, 0.36 mmol), acetic anhydride (35 μL, 5.76 mmol) and DMAP (cat.). The resulting mixture was stirred at rt for 1 hour. H₂O (5 mL) was added and the aqueous phase was extracted with CH₂Cl₂ (2 x 25 mL). The combined organic phases were washed with 10% HCl solution (5 mL), dried with Na₂SO₄, filtered and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 5% EtOAc/hexane), affording compound **27** (51 mg, 91%).

Compound **27**: colourless liquid; R_f: 0.43 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 2956, 2923, 2853, 1745, 1462, 1377, 1229, 1081, 967.

[α]_D²⁰ = +15.14 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.66 (1H, m, H-1'), 5.56 (1H, m, H-21), 5.41 (1H, m, H-16), 5.19 (2H, m, H-23/24), 4.52 (2H, dd, *J*=6.3/1.1 Hz, H-2'), 3.36 (2H, s, MeO), 2.80 (1H, m, H-6), 2.75 (1H, m, H-20), 2.55 (1H, m), 2.29 (1H, m), 2.11 (2H, m), 2.06 (3H, s, H-4'), 1.94 (3H, m), 1.75 (2H, m), 1.53 (3H, m), 1.35 (2H, m), 1.16 (1H, m), 1.06 (3H, s, CH₃-18), 0.95 (3H, s, CH₃-26/27), 0.93 (3H, s, CH₃-26/27), 0.89 (4H, m), 0.82 (3H, s, CH₃-19), 0.67 (1H, dd, *J*=5.1/3.7 Hz, H-4), 0.46 (1H, dd, *J*=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 170.8 (C=O), 157.1 (C-17), 139.6 (CH), 138.2 (CH), 125.1 (CH), 123.2 (CH), 123.0 (CH), 82.3 (CH-6), 65.0 (CH₂-2'), 57.4 (CH), 56.6 (MeO), 48.6 (CH), 47.5 (C-10), 43.6 (C-13), 41.7 (CH₂), 35.4 (C-5), 35.1 (CH₂), 33.1 (CH₂), 32.4 (CH₂), 31.2 (CH₂), 29.0 (CH), 26.6 (CH-25), 24.9 (CH₂), 23.1 (CH₃-26/27), 23.0 (CH₃-26/27), 22.7 (CH₂), 22.4 (CH₂), 21.4 (CH), 21.0 (CH₃-4'), 19.3 (CH₃-18), 16.9 (CH₃-19), 13.1 (CH₂-4) ppm.

MS (ESI⁺) (*m/z*, %): 520.32 (M⁺+K, 13), 503.35 (M⁺+Na, 13), 449.34 (M⁺-OMe, 95), 421.34 (M⁺-OAc, 23).

HRMS (ESI⁺): 503.3496 calculated for C₃₂H₄₈NaO₃ and found 503.3492.

1.32. Synthesis of (1*aR*,3*aR*,3*bS*,5*aS*,8*aS*,8*bR*,10*R*,10*aR*)-6-((*R*,3*E*,7*E*)-2,10-dimethyl-10-nitroundeca-3,7-dien-6-yl)-10-methoxy-3*a*,5*a*-dimethyl-1,1*a*,2,3,3*a*,3*b*,4,5,5*a*,8,8*a*,8*b*,9,10-tetradecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalene (**28**)



To a solution of $\text{Pd}(\text{PPh}_3)_4$ (12 mg, 0.42 mmol), Cs_2CO_3 (137 mg, 0.42 mmol) and 2-nitropropane (38 μL , 0.42 mmol) in DMSO (2 mL) was added the solution of acetate **27** (632 mg, 1.6 mmol) in DMSO (1 mL). The resulting mixture was stirred at rt for 25 hours. A saturated aqueous solution of NH_4Cl (8 mL) was added and the aqueous solution was extracted with *t*BuOMe (3x20 mL). The combined organic phases were dried with Na_2SO_4 , filtered and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 3% EtOAc/hexane), affording compound **28** (40 mg, 75%).

Compound **28**: colourless liquid; Rf: 0.32 (5% EtOAc/hexane).

IR (ATR, cm^{-1}): 2955, 2922, 2852, 1541, 1463, 1372, 1095, 970.

$[\alpha]_D^{20} = +16.25$ (c 1.00, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 5.47 (1H, m), 5.39 (1H, s, H-16), 5.21 (3H, m), 3.36 (3H, s, MeO), 2.81 (1H, s, H-6), 2.72 (1H, m, H-20), 2.58 (3H, m, H25/H-2'), 2.28 (1H, m), 2.09 (2H, m), 1.94 (2H, m), 1.76 (2H, m), 1.57 (6H, s, H-4'/5'), 1.51 (3H, m), 1.33 (3H, m), 1.17 (1H, m), 1.07 (3H, s, CH_3 -18), 0.96 (3H, d, $J=2.1$ Hz, CH_3 -26/27), 0.93 (3H, d, $J=2.0$ Hz, CH_3 -26/27), 0.91 (3H, m), 0.82 (3H, s, CH_3 -19), 0.68 (1H, dd, $J=5.1/3.7$ Hz, H-4), 0.47 (1H, dd, $J=8.0/5.1$ Hz, H-4) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 157.5 (C-17), 140.4 (CH), 138.1 (CH), 125.4 (CH), 122.9 (CH), 121.6 (CH), 88.1 (C-3'), 82.4 (CH-6), 57.3 (CH), 56.6 (MeO), 48.6 (CH), 47.5 (C-10), 43.9 (CH_2), 43.6 (C-13), 42.0 (CH), 35.4 (C-5), 35.1 (CH_2), 33.1 (CH_2), 32.7 (CH_2), 31.2 (CH_2), 29.0 (CH), 26.7 (CH-25), 25.6 (CH_3 -4'/5'), 25.5 (CH_3 -4'/5'), 24.9 (CH_2), 23.1 (CH_3 -26/27), 23.0 (CH_3 -26/27), 22.3 (CH_2), 21.4 (CH), 19.3 (CH_3 -18), 16.9 (CH_3 -19), 13.1 (CH_2 -4) ppm.

MS (ESI⁺) (m/z, %): 478.36 (M^+ -OMe, 100).

HRMS (ESI⁺): 478.3680 calculated for $\text{C}_{32}\text{H}_{48}\text{NO}_2$ and found 478.3673.

1.33. Synthesis of (1*aR*,3*aR*,3*bS*,5*aR*,8*aS*,8*bS*,10*R*,10*aR*)-6-((*R*)-2,10-dimethyl-2-nitrodec-6-yl)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalene (**42**)



To a suspension of compound **28** (40 mg, 0.078 mmol) and Pd/C (10%) (cat.) in EtOAc (2 mL) was stirred at rt under atmosphere of H₂ for 16 hours. The mixture was then filtered through and the filtered liquids was concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 2% EtOAc/hexane), affording the compound **42** (36 mg, 90%).

Compound **42**: colourless liquid; R_f: 0.62 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 2950, 2922, 2852, 1541, 1463, 1375, 1099, 721.

[α]_D²⁰ = +13.84 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.34 (3H, s, MeO), 2.79 (1H, s, H-6), 1.92 (4H, m), 1.76 (3H, m), 1.59 (6H, s, CH₃-4'/5'), 1.53 (5H, m), 1.41 (5H, m), 1.28 (7H, m), 1.13 (9H, m), 1.04 (3H, s, CH₃-18), 0.91 (2H, m), 0.89 (3H, s, CH₃-26/27), 0.88 (3H, s, CH₃-26/27), 0.72 (3H, s, CH₃-19), 0.66 (1H, dd, J=5.1/3.7 Hz, H-4), 0.45 (1H, dd, J=8.0/5.0 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 88.3 (C-3'), 82.4 (CH-6), 56.6 (MeO), 56.5 (CH), 52.6 (CH), 48.1 (CH), 43.4 (C-10), 42.9 (C-13), 41.6 (CH₂), 40.0 (CH₂), 39.5 (CH₂), 39.0 (CH), 35.3 (C-5), 35.0 (CH₂), 33.4 (CH₂), 30.8 (CH₂), 30.8 (CH₂), 30.5 (CH), 28.0 (CH), 27.8 (CH₂), 26.0 (CH₃-4'/5'), 25.8 (CH₃-4'/5'), 25.0 (CH₂), 24.1 (CH₂), 22.9 (CH₂), 22.8 (CH₂), 22.7 (CH₃-26/27), 22.7 (CH₃-26/27), 21.5 (CH), 20.1 (CH₂), 19.3 (CH₃-18), 13.1 (CH₂-4), 12.4 (CH₃-19) ppm.

MS (ESI⁺) (m/z, %): 484.41 (M⁺-OMe, 100).

HRMS (ESI⁺): 484.4149 calculated for C₃₂H₅₄NO₂ and found 484.4141.

1.34. Synthesis of (3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-17-((*R*)-2,10-dimethyl-2-nitroundecan-6-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (**43**)



To a solution of compound **42** (35 mg, 0.068 mmol) in dioxane (2 mL) and H₂O (0.5 mL) was added *p*-TsOH (cat.) and the resulting mixture was stirred at 80 °C for 3 hours. H₂O (5 mL) was added and the aqueous solution was extracted with CH₂Cl₂ (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 30% EtOAc/hexane), affording the alcohol **43** (33 mg, 97%).

Compound **43**: colourless liquid; R_f: 0.10 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 3340, 2950, 2923, 2886, 1539, 1463, 1375, 1055.

[α]_D²³ = -21.31 (c 0.5, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.36 (1H, m, H-6), 3.54 (1H, m, H-3), 2.29 (2H, m), 1.97 (2H, m), 1.84 (3H, m), 1.72 (2H, m), 1.59 (6H, s, CH₃-4'/5'), 1.51 (3H, m), 1.41 (3H, m), 1.27 (6H, m), 1.13 (6H, m), 1.02 (3H, s, CH₃-18), 0.92 (2H, m), 0.89 (3H, s, CH₃-26/27), 0.88 (3H, s, CH₃-26/27), 0.68 (3H, s, CH₃-19) ppm.

¹³C-NMR (CDCl₃, δ): 140.8 (C-5), 121.7 (CH-6), 88.3 (C-3'), 71.8 (CH-3), 56.7 (MeO), 52.4 (CH), 50.1 (CH), 42.4 (C-13), 42.3 (CH₂), 41.6 (CH₂), 39.5 (CH₂), 39.5 (CH₂), 39.0 (CH), 37.3 (CH₂), 36.5 (C-10), 31.9 (CH), 31.9 (CH₂), 31.6 (CH₂), 30.8 (CH₂), 30.8 (CH₂), 27.9 (CH), 27.8 (CH₂), 25.9 (CH₃-4'/5'), 25.8 (CH₃-4'/5'), 24.2 (CH₂), 22.8 (CH₂), 22.7 (CH₃-26/27), 22.6 (CH₃-26/27), 21.1 (CH₂), 20.0 (CH₂), 19.4 (CH₃-18), 12.0 (CH₃-19) ppm.

MS (ESI+) (m/z, %): 484.41 (M⁺-OH, 100).

HRMS (ESI⁺): 484.4149 calculated for C₃₂H₅₄NO₂ and found 484.4140.

1.35. Synthesis of (3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-17-((*R*)-2-amino-2,10-dimethylundecan-6-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (**6**)



To a solution of compound **43** (30 mg, 0.065 mmol) in THF (2 mL) was added LiAlH_4 (10 mg, 0.263 mmol). The resulting mixture was stirred at $70\text{ }^\circ\text{C}$ for 24 hours. 4 M aqueous solution of NaOH (5 mL) was added and the aqueous was extracted with Et_2O (4x15 mL). The combined organic phases were dried with Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 70% EtOAc/hexane), affording the compound **6** (6 mg, 20%).

Compound **6**: colourless liquid; Rf: 0.10 (30% EtOAc/hexane).

IR (ATR, cm^{-1}): 3379, 2954, 2923, 2853, 1640, 1463, 1377, 1037.

$[\alpha]_{\text{D}}^{23} = -31.43$ (c 0.5, CHCl_3).


$^1\text{H-NMR}$ (CDCl_3 , δ): 5.34 (1H, m, H-6), 3.51 (1H, m, H-3), 2.27 (2H, m), 1.94 (2H, m), 1.82 (2H, m), 1.75 (2H, m), 1.59-1.09 (23H, m), 1.08 (6H, s, H-4'/5'), 1.00 (3H, s, CH_3 -18), 0.86 (3H, s, CH_3 -26/27), 0.84 (3H, s, CH_3 -26/27), 0.65 (3H, s, CH_3 -19) ppm.

$^{13}\text{C-NMR}$ (CDCl_3 , δ): 140.8 (C-5), 121.7 (CH-6), 71.8 (CH-3), 68.3 (C-3'), 56.7 (MeO), 52.6 (CH), 50.2 (CH), 42.4 (C-13), 42.3 (CH_2), 41.3 (CH_2), 39.7 (CH_2), 39.5 (CH_2), 39.2 (CH), 37.3 (CH_2), 36.5 (C-10), 31.9 (CH), 31.9 (CH_2), 31.7 (CH_2), 31.6 (CH_2), 31.0 (CH_2), 28.0 (CH), 27.8 (CH_2), 24.7 (CH_3 -4'/5'), 24.6 (CH_3 -4'/5'), 24.2 (CH_2), 22.8 (CH_2), 22.8 (CH_3 -26/27), 22.7 (CH_3 -26/27), 21.1 (CH_2), 19.6 (CH_2), 19.4 (CH_3 -18), 12.0 (CH_3 -19) ppm.

MS (ESI⁺) (*m/z*, %): 530.45 (100), 472.45 (M^++1 , 19).

HRMS (ESI⁺): 472.4513 calculated for $\text{C}_{32}\text{H}_{58}\text{NO}$ and found 472.4505.

1.36. Synthesis of (S)-2-((1aR,3aR,3bS,5aS,6R,8aS,8bS,10R,10aR)-10-methoxy-3a,5a-dimethylhexadecahydrocyclopenta[a]cyclopropa[2,3]cyclopenta[1,2-f]naphthalen-6-yl)-6-methylheptan-1-ol (22)



To a suspension of compound **7** (125 mg, 0.3 mmol) and Pd/C (10%) (cat.) in EtOAc (3 mL) was stirred at rt under atmosphere of H₂ for 14 hours. The mixture was then filtered through and the filtered liquids was concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 1% EtOAc/hexane), affording the compound **22** (92 mg, 74%).

Compound **22**: colourless liquid; R_f: 0.84 (50% EtOAc/hexane).

IR (ATR, cm⁻¹): 3325, 2924, 2923, 2849, 1473 1181, 1121, 724.

[α]_D²³ = -79.89 (c 0.25, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.70 (1H, dd, J=10.9/2.7 Hz, H-21), 3.53 (1H, dd, J=10.9/4.5 Hz, H-21), 3.32 (3H, s, MeO), 2.77 (1H, m, H-6), 1.92 (3H, m), 1.75 (3H, m), 1.52 (4H, m), 1.41 (6H, m), 1.18 (8H, m), 1.03 (3H, s, CH₃-18), 0.88 (3H, s, CH₃-26/27), 0.87 (3H, s, CH₃-26/27), 0.83 (3H, m), 0.74 (3H, s, CH₃-19), 0.65 (1H, dd, J=5.1/3.7 Hz, H-4), 0.43 (1H, dd, J=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 82.4 (CH-6), 63.5 (CH₂-21), 56.5 (MeO), 56.3 (CH-14), 50.3 (CH), 48.0 (CH), 43.4 (C-10), 42.8 (C-13), 42.4 (CH), 40.1 (CH₂), 39.5 (CH₂), 35.3 (C-5), 35.1 (CH₂), 33.4 (CH₂), 30.6 (CH), 29.4 (CH₂), 28.0 (CH), 27.5 (CH₂), 25.0 (CH₂), 24.1 (CH₂), 23.8 (CH₂), 22.8 (CH₂), 22.7 (CH₃-26/27), 22.7 (CH₃-26/27), 21.5 (CH), 19.3 (CH₃-18), 13.1 (CH₂-4), 12.5 (CH₃-19) ppm.

MS (ESI⁺) (m/z, %): 385.34 (M⁺-OMe, 100).

HRMS (ESI⁺): 385.3465 calculated for C₂₇H₄₅O and found 385.3464.

1.37. Synthesis of (1*aR*,3*aR*,3*bS*,5*aS*,6*R*,8*aS*,8*bS*,10*R*,10*aR*)-6-((*S*)-1-iodo-6-methylheptan-2-yl)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalene (**29**)



To a solution of diol **22** (72 mg, 0.173 mmol) in THF (43 mL) were added sequentially PPh₃ (69 mg, 0.26 mmol) and imidazole (36 mg, 0.52 mmol). After cooling the mixture to 0 °C, I₂ (62 mg, 0.242 mmol) was added and stirring continued at rt for 20 minutes. The reaction was quenched with an aqueous saturated solution of NaHCO₃ (5 mL) and the product extracted with EtOAc (3x10 mL). The combined organic phase was washed with a 10% aqueous solution of Na₂S₂O₃ (10 mL), dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 1% EtOAc/hexane), affording the compound **29** (90 mg, 99%).

Compound **29**: colourless liquid; R_f: 0.85 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 2952, 2924, 2850, 1462, 1183, 1119, 721, 540.

[α]_D²⁰ = +15.80 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.46 (1H, dd, *J*=9.9/2.8 Hz, H-21), 3.36 (3H, s, MeO), 3.28 (1H, dd, *J*=9.9/4.1 Hz, H-21), 2.81 (1H, m, H-6), 1.95 (4H, m), 1.79 (2H, m), 1.69 (2H, m), 1.57 (5H, m), 1.46 (2H, m), 1.22 (10H, m), 1.07 (3H, s, CH₃-18), 0.93 (6H, d, *J*=6.6 Hz, CH₃-26/27), 0.87 (3H, m), 0.82 (3H, s, CH₃-19), 0.69 (1H, dd, *J*=5.1/3.6 Hz, H-4), 0.48 (1H, dd, *J*=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 82.4 (CH-6), 56.6 (MeO), 56.4 (CH-14), 53.9 (CH), 48.0 (CH), 43.4 (C-10), 42.7 (C-13), 40.6 (CH), 40.2 (CH₂), 39.0 (CH₂), 35.3 (C-5), 35.1 (CH₂), 33.4 (CH₂), 32.5 (CH₂), 30.6 (CH), 28.0 (CH), 27.5 (CH₂), 25.0 (CH₂), 24.0 (CH₂), 23.7 (CH₂), 22.85 (CH₃-26/27), 22.6 (CH), 21.5 (CH), 19.3 (CH₃-18), 18.5 (CH₂-21), 13.3 (CH₃-19), 13.2 (CH₂-4) ppm.

MS (ESI⁺) (*m/z*, %): 557.18 (M⁺+OMe, 100), 495.25 (M⁺-OMe, 40).

HRMS (ESI⁺): 495.2482 calculated for C₂₇H₄₄I and found 495.2489.

1.38. Synthesis of ethyl (*R*)-5-((1*aR*,3*aR*,3*bS*,5*aR*,6*R*,8*aS*,8*bS*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-9-methyldecanoate (**30**)



To a suspension of Zn (167 mg, 2.55 mmol) in pyridine (4 mL) was added NiCl₂·6H₂O (121 mg, 0.51 mmol) and ethyl acrylate (0.28 mL, 2.55 mmol) and the resulting mixture was stirred at 65 °C. It was observed that the suspension acquires a reddish-brown colour. After 30 minutes the mixture was cooled to 0 °C and was added a solution of the iodide **29** (90 mg, 0.17 mmol) in pyridine (2 mL) and it was stirred under these conditions for 90 minutes. Once the reaction mixture reaches rt, EtOAc (10 mL) was added and the resulting suspension was filtered over celite. The filtered liquids were washed with a 10% solution of CuSO₄ (3x20 mL), H₂O (2x20 mL) and a saturated solution of NaCl (15 mL). The organic phase was dried with Na₂SO₄, filtered and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 7% EtOAc/hexane), affording the compound **30** (69 mg, 82%).

Compound **30**: colourless liquid; R_f: 0.41 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 2950, 2927, 2867, 1737, 1460, 1373, 1163, 1098.

[α]_D²² = +14.93 (c 0.5, CHCl₃).


¹H-NMR (CDCl₃, δ): 4.14 (2H, q, *J*=7.5 Hz, CH₂-OEt), 3.33 (3H, s, MeO), 2.77 (1H, m, H-6), 2.26 (2H, m, H-2'), 1.92 (2H, m), 1.75 (3H, m), 1.61 (2H, m), 1.52 (4H, m), 1.42 (5H, m), 1.31 (5H, m), 1.26 (3H, t, *J*=7.5 Hz, CH₃-OEt), 1.14 (7H, m), 1.03 (3H, s, CH₃-18), 0.87 (6H, d, *J*=6.6 Hz, CH₃-26/27), 0.85 (3H, m), 0.71 (3H, s, CH₃-19), 0.65 (1H, dd, *J*=5.1/3.7 Hz, H-4), 0.43 (1H, dd, *J*=8.1/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 173.9 (C=O), 82.4 (CH-6), 60.1 (CH₂-OEt), 56.5 (MeO), 56.5 (CH-14), 52.6 (CH), 48.1 (CH), 43.4 (C-10), 42.8 (C-13), 40.0 (CH₂), 39.5 (CH₂), 39.1 (CH), 35.3 (C-5), 35.0 (CH₂), 34.9 (CH₂), 33.4 (CH₂), 30.8 (CH₂), 30.5 (CH), 30.4 (CH₂), 28.0 (CH), 27.8 (CH₂), 25.0 (CH₂), 24.1 (CH₂), 23.0 (CH₂), 22.8 (CH₂), 22.7 (CH₃-26/27), 22.7 (CH₃-26/27), 21.5 (CH₂), 21.0 (CH), 19.3 (CH₃-18), 14.3 (CH₃-OEt), 13.1 (CH₂-4), 12.3 (CH₃-19) ppm.

MS (ESI⁺) (*m/z*, %): 469.40 (M⁺-OMe, 100), 427.35 (10).

HRMS (ESI⁺): 469.4040 calculated for C₃₂H₅₃O₂ and found 469.4041.

1.39. Synthesis of (*R*)-6-((1*aR*,3*aR*,3*bS*,5*aR*,6*R*,8*aS*,8*bS*,10*R*,10*aR*)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalen-6-yl)-2,10-dimethylundecan-2-ol (**44**)



To a solution of compound **30** (69 mg, 0.137 mmol) in THF (2 mL) cooled to $-78\text{ }^{\circ}\text{C}$ was added a 1.5 M solution of MeLi·LiBr in Et₂O (0.46 mL, 0.69 mmol) and the resulting mixture was stirred in these conditions for 14 hours. H₂O (10 mL) was added and the aqueous solution was extracted with CH₂Cl₂ (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 10% EtOAc/hexane), affording the alcohol **44** (56 mg, 86%).

Compound **44**: colourless liquid; R_f: 0.20 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 3374, 2951, 2925, 2866, 1465, 1378, 1098.

[α]_D²⁰ = +13.11 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.33 (3H, s, MeO), 2.78 (1H, m, H-6), 1.92 (3H, m), 1.75 (4H, m), 1.53 (5H, m), 1.43 (7H, m), 1.31 (6H, m), 1.22 (6H, s, CH₃-4'/5'), 1.13 (5H, m), 1.04 (3H, s, CH₃-18), 0.88 (6H, d, J=6.6 Hz, CH₃-26/27), 0.85 (3H, m), 0.72 (3H, s, CH₃-19), 0.66 (1H, dd, J=5.1/3.7 Hz, H-4), 0.44 (1H, dd, J=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 82.4 (CH-6), 71.1 (C-3'), 56.5 (MeO), 56.5 (CH-14), 52.7 (CH), 48.1 (CH), 44.6 (CH₂), 43.4 (C-10), 42.9 (C-13), 40.0 (CH₂), 39.6 (CH₂), 39.2 (CH), 35.3 (C-5), 35.1 (CH₂), 33.4 (CH₂), 31.5 (CH₂), 30.9 (CH₂), 30.5 (CH), 29.3 (CH₃-4'/5'), 29.2 (CH₃-4'/5'), 28.0 (CH), 27.9 (CH₂), 25.0 (CH₂), 24.1 (CH₂), 22.9 (CH₂), 22.8 (CH₂), 22.8 (CH₃-26/27), 22.7 (CH₃-26/27), 21.5 (CH), 20.2 (CH₂), 19.3 (CH₃-18), 13.1 (CH₂-4), 12.4 (CH₃-19) ppm.

MS (ESI⁺) (m/z, %): 509.43 (M⁺+Na, 1), 455.42 (M⁺-OMe, 25), 437.41 (100).

HRMS (ESI⁺): 509.4329 calculated for C₃₃H₅₈NaO₂ and found 509.4337.

1.40. Synthesis of (3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-17-((*R*)-2-hydroxy-2,10-dimethylundecan-6-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (**4**)



To a solution of compound **44** (56 mg, 0.115 mmol) in dioxane (2 mL) and H₂O (0.5 mL) was added *p*-TsOH (cat.) and the resulting mixture was stirred at 80 °C for 3 hours. H₂O (5 mL) was added and the aqueous solution was extracted with CH₂Cl₂ (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 30% EtOAc/hexane), affording the diol **4** (33 mg, 94%).

Compound **4**: white solid (mp: 146-151 °C); R_f: 0.46 (30% EtOAc/hexane).

IR (ATR, cm⁻¹): 3289, 2929, 2883, 2864, 1464, 1364, 1190, 939.

[α]_D²³ = -39.19 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.36 (1H, m, H-6), 3.54 (1H, m, H-3), 2.28 (2H, m), 1.97 (2H, m), 1.86 (2H, m), 1.78 (1H, m), 1.69-1.25 (24H, m), 1.23 (6H, s, CH₃-4'/5'), 1.15 (5H, m), 1.02 (3H, s, CH₃-18), 0.88 (6H, d, *J*=6.6 Hz, CH₃-26/27), 0.69 (3H, s, CH₃-19) ppm.

¹³C-NMR (CDCl₃, δ): 140.8 (C-5), 121.7 (CH-6), 71.8 (CH-3), 71.1 (C-3'), 56.7 (MeO), 52.6 (CH), 50.2 (CH), 44.6 (CH₂), 42.4 (C-10), 42.3 (CH₂), 39.6 (CH₂), 39.5 (CH₂), 39.2 (CH), 37.3 (CH₂), 36.5 (C-13), 32.0 (CH), 31.9 (CH₂), 31.7 (CH₂), 31.4 (CH₂), 30.9 (CH₂), 29.3 (CH₃-4'/5'), 29.2 (CH₃-4'/5'), 28.0 (CH), 27.8 (CH₂), 24.2 (CH₂), 22.9 (CH₂), 22.8 (CH₃-26/27), 22.7 (CH₃-26/27), 21.1 (CH₂), 20.1 (CH₂), 19.4 (CH₃-18), 12.0 (CH₃-19) ppm.

MS (ESI⁺) (*m/z*, %): 495.42 (M⁺+Na, 1), 455.43 (M⁺-OH, 100), 437.41 (60).

HRMS (ESI⁺): 495.4172 calculated for C₃₂H₅₆NaO₂ and found 495.4267.

1.41. Synthesis of (S)-2-((1aR,3aR,3bS,5aS,6R,8aS,8bS,10R,10aR)-10-methoxy-3a,5a-dimethylhexadecahydrocyclopenta[a]cyclopropa[2,3]cyclopenta[1,2-f]naphthalen-6-yl)-6-methylheptyl 4-methylbenzenesulfonate (**23**)



To a solution of compound **22** (54 mg, 0.129 mmol) in CH_2Cl_2 (2 mL) was added *p*-TsCl (75 mg, 0.39 mmol), *n*-BuSnO₂ (cat.) and Et₃N (0.11 mL, 0.78 mmol). The resulting mixture was stirred at rt for 2 hours. Then *p*-TsCl (0.39 mmol) and Et₃N (0.78 mmol) was added again and was stirred for 10 days. H₂O (10 mL) was added and the aqueous phase was extracted with CH_2Cl_2 (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 10% EtOAc/hexane), affording the compound **23** (57 mg, 78%).

Compound **23**: colourless liquid; R_f: 0.67 (20% EtOAc/hexane).

IR (ATR, cm⁻¹): 2952, 2917, 2848, 1463, 1177, 1097, 944.

[α]_D²⁴ = -38.63 (c 0.5, CHCl₃).


¹H-NMR (CDCl₃, δ): 7.80 (2H, dd, *J*=8.3 Hz, H-Ts), 7.36 (2H, dd, *J*=8.5 Hz, H-Ts), 4.05 (1H, dd, *J*=9.5/2.9 Hz, H-21), 3.92 (1H, dd, *J*=9.4/4.8 Hz, H-21), 3.33 (3H, s, MeO), 2.78 (1H, s, H-6), 2.46 (3H, s, CH₃-Ts), 1.88 (2H, m), 1.72 (3H, m), 1.54 (5H, m), 1.41 (3H, m), 1.28 (2H, m), 1.07 (6H, m), 1.02 (3H, s, CH₃-18), 0.89 (6H, m), 0.82 (6H, dd, *J*=6.6/2.9 Hz, CH₃-26/27), 0.68 (3H, s, CH₃-19), 0.66 (1H, m, H-4), 0.44 (1H, dd, *J*=8.1/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 144.6 (C-OTs), 133.0 (C-Ts), 129.7 (CH-Ts), 127.9 (CH-Ts), 82.3 (CH-6), 71.7 (CH₂-21), 56.6 (MeO), 56.2 (CH), 49.9 (CH), 47.9 (CH), 43.4 (C-10), 42.8 (C-13), 42.0 (CH₂), 40.3 (CH), 39.9 (CH₂), 39.1 (CH₂), 35.2 (C-5), 35.0 (CH₂), 33.4 (CH₂), 30.6 (CH), 29.3 (CH₂), 27.9 (CH), 27.3 (CH₂), 24.9 (CH₂), 24.0 (CH₂), 23.5 (CH₂), 22.8 (CH₂), 22.6 (CH₃-26/27), 22.5 (CH₃-26/27), 21.6 (CH), 21.5 (CH), 19.3 (CH₃-18), 14.2 (CH₃-Ts), 13.1 (CH₂-4), 12.3 (CH₃-19) ppm.

MS (ESI⁺) (*m/z*, %): 593.36 (M⁺+Na, 1), 539.35 (M⁺-OMe, 50), 399.36 (M⁺-OTs, 1).

HRMS (ESI⁺): 593.3635 calculated for C₃₅H₅₄NaO₄S and found 593.3635.

1.42. Synthesis of (1a*R*,3a*R*,3b*S*,5a*R*,6*R*,8a*S*,8b*S*,10*R*,10a*R*)-10-methoxy-3a,5a-dimethyl-6-((*S*)-6-methylheptan-2-yl)hexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalene (**45**)



To a solution of compound **23** (20 mg, 0.035 mmol) in Et₂O (1 mL) cooled to 0 °C was added dropwise a solution of LiAlH₄ (20 mg, 0.53 mmol) in Et₂O (1 mL). The resulting mixture was stirred at rt for 16 hours. H₂O (5 mL) was added and the aqueous was extracted with Et₂O (4x15 mL), The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 1% EtOAc/hexane), affording the compound **45** (10 mg, 75%).

Compound **45**: colourless liquid; R_f: 0.95 (20% EtOAc/hexane).

IR (ATR, cm⁻¹): 2955, 2917, 2849, 1462, 1378, 1098, 966, 720.

[α]_D²³ = -17.92 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.34 (3H, s, MeO), 2.79 (1H, s, H-6), 1.94 (2H, m), 1.75 (3H, m), 1.54 (6H, m), 1.43 (5H, m), 1.31 (4H, m), 1.15 (7H, m), 1.04 (3H, s, CH₃-18), 0.89 (6H, d, *J*=6.6 Hz, CH₃-26/27), 0.84 (3H, d, *J*=6.5 Hz, CH₃-21), 0.74 (3H, s, CH₃-19), 0.67 (1H, m, H-4), 0.45 (1H, dd, *J*=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 82.5 (CH-6), 56.6 (MeO), 56.6 (CH), 55.9 (CH), 48.1 (CH), 43.4 (C-10), 42.8 (C-13), 40.2 (CH₂), 39.5 (CH₂), 35.6 (CH₂), 35.2 (C-5), 35.1 (CH₂), 33.4 (CH₂), 30.5 (CH), 28.1 (CH₂), 28.1 (CH), 25.0 (CH₂), 24.1 (CH₂), 24.0 (CH₂), 22.8 (CH₂), 22.8 (CH), 22.7 (CH), 21.6 (CH), 19.3 (CH₃-18), 18.7 (CH₃-21), 13.1 (CH₂-4), 12.5 (CH₃-19) ppm.

MS (ESI⁺) (m/z, %): 369.35 (M⁺-OMe, 100).

HRMS (ESI⁺): 369.3516 calculated for C₂₇H₄₅ and found 369.3514.

1.43. Synthesis of (3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-10,13-dimethyl-17-((*S*)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (**2**)



To a solution of compound **45** (10 mg, 0.115 mmol) in dioxane (1 mL) and H₂O (0.25 mL) was added *p*-TsOH (cat.) and the resulting mixture was stirred at 80 °C for 3 hours. H₂O (5 mL) was added and the aqueous solution was extracted with CH₂Cl₂ (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 10% EtOAc/hexane), affording the diol **2** (10 mg, 99%).

Compound **2**: white solid (mp: 142-149 °C); R_f: 0.20 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 3252, 2955, 2920, 2850, 1462, 1376, 1080, 968.

[α]_D²⁴ = -79.84 (c 0.5, CHCl₃).


¹H-NMR (CDCl₃, δ): 5.38 (1H, s, H-6), 3.55 (1H, m, H-3), 2.30 (2H, m), 2.02 (2H, m), 1.85 (3H, m), 1.59 (10H, m), 1.29 (3H, m), 1.15 (7H, m), 1.03 (3H, s, CH₃-18), 0.95 (1H, m), 0.89 (6H, d, *J*=6.6 Hz, CH₃-26/27), 0.84 (3H, d, *J*=6.6 Hz, CH₃-21), 0.70 (3H, s, CH₃-19) ppm.

¹³C-NMR (CDCl₃, δ): 140.8 (C-5), 121.7 (CH-6), 71.8 (CH-3), 56.8 (CH), 55.8 (CH), 50.2 (CH), 42.4 (C-13), 42.3 (CH₂), 39.7 (CH₂), 39.5 (CH₂), 37.3 (CH₂), 36.5 (CH), 35.7 (CH₂), 35.3 (CH), 31.9 (C-10), 31.7 (CH), 28.1 (CH), 28.1 (CH₂), 24.2 (CH₂), 23.9 (CH₂), 22.8 (CH), 22.8 (CH₃-26/27), 21.1 (CH₂), 19.4 (CH₃-18), 18.7 (CH₃-21), 12.1 (CH₃-19) ppm.

MS (ESI⁺) (*m/z*, %): 369.35 (M⁺-OH, 100).

HRMS (ESI⁺): 369.3516 calculated for C₂₇H₄₅ and found 369.3505.

1.44. Synthesis of (1*aR*,3*aR*,3*bS*,5*aS*,6*R*,8*aS*,8*bS*,10*R*,10*aR*)-6-((*S*)-1-azido-6-methylheptan-2-yl)-10-methoxy-3*a*,5*a*-dimethylhexadecahydrocyclopenta[*a*]cyclopropa[2,3]cyclopenta[1,2-*f*]naphthalene (**24**)



To a solution of compound **23** (31 mg, 0.054 mmol) in DMF (2 mL) was added NaN₃ (35 mg, 0.543 mmol). The resulting mixture was stirred at 50 °C for 3 hours. H₂O (5 mL) was added and the aqueous phase was extracted with EtOAc (3x10mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 5% EtOAc/hexane), affording the azide **24** (17 mg, 71%).

Compound **24**: colourless liquid; R_f: 0.69 (10% EtOAc/hexane).

IR (ATR, cm⁻¹): 2953, 2916, 2848, 2095, 1462, 1264, 1098, 735.

[α]_D²³ = +7.88 (c 1.00, CHCl₃).


¹H-NMR (CDCl₃, δ): 3.48 (1H, dd, *J*=12.3/3.1 Hz, H-21), 3.35 (3H, s, MeO), 3.24 (1H, dd, *J*=12.3/5.6 Hz, H-21), 2.79 (1H, s, H-6), 1.93 (2H, m), 1.76 (2H, m), 1.65 (1H, m), 1.56 (6H, m), 1.37 (7H, m), 1.18 (6H, m), 1.05 (3H, s, CH₃-18), 0.90 (6H, d, *J*=6.6 Hz, CH₃-26/27), 0.85 (3H, m), 0.75 (3H, s, CH₃-19), 0.67 (1H, dd, *J*=5.0/3.8 Hz, H-4), 0.46 (1H, dd, *J*=8.0/5.1 Hz, H-4) ppm.

¹³C-NMR (CDCl₃, δ): 82.4 (CH-6), 56.6 (MeO), 56.4 (CH-14), 53.9 (CH), 48.0 (CH), 43.4 (C-10), 42.7 (C-13), 40.6 (CH), 40.2 (CH₂), 39.0 (CH₂), 35.3 (C-5), 35.1 (CH₂), 33.4 (CH₂), 32.5 (CH₂), 30.6 (CH), 28.0 (CH), 27.5 (CH₂), 25.0 (CH₂), 24.0 (CH₂), 23.7 (CH₂), 22.9 (CH₃-26/27), 22.6 (CH), 21.5 (CH), 19.3 (CH₃-18), 18.5 (CH₂-21), 13.3 (CH₃-19), 13.2 (CH₂-4) ppm.

MS (ESI⁺) (*m/z*, %): 410.35 (M⁺-OMe, 100), 382.34 (80).

HRMS (ESI⁺): 410.3530 calculated for C₂₇H₄₄N₃ and found 410.3520.

1.45. Synthesis of (3*S*,8*S*,9*S*,10*R*,13*S*,14*S*,17*R*)-17-((*S*)-1-(4-(2-hydroxypropan-2-yl)-1*H*-1,2,3-triazol-1-yl)-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (**5**)



To a solution of azide **24** (17 mg, 0.038 mmol) in *t*BuOH (2 mL) and H₂O (1 mL) was added CuSO₄·5H₂O (cat.), an aqueous solution of 1 M sodium ascorbate (10 μl, 0.007 mmol) and 2-methyl-3-butyn-2-ol (5 μl, 0.04 mmol). The resulting mixture was stirred at rt for 5 hours. Then *p*-TsOH (cat.) was added and heated at 80 °C for 3 hours. H₂O (3 mL) was added and the aqueous phase was extracted with CH₂Cl₂ (3x15 mL). The combined organic phases were dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (mobile phase: 50% EtOAc/hexane), affording the diol **5** (11 mg, 60%).

Compound **5**: colourless solid (mp: 232-236 °C); R_f: 0.10 (30% EtOAc/hexane).

IR (ATR, cm⁻¹): 3401, 2956, 2923, 2853, 1463, 1378, 1187, 967.





[α]_D²⁴ = -29.85 (c 1.00, CHCl₃).




¹H-NMR (CDCl₃, δ): 7.36 (1H, s, H-1'), 5.35 (1H, s, H-6), 4.32 (1H, m, H-21), 4.23 (1H, m, H-21), 3.52 (1H, m, H-3), 2.26 (3H, m), 1.94 (6H, m), 1.83 (5H, m), 1.48 (8H, m), 1.27 (5H, m), 1.23 (6H, d, *J*=9.2 Hz, CH₃-4'/5'), 1.06 (3H, m), 1.00 (3H, s, CH₃-18), 0.84 (6H, d, *J*=6.6 Hz, CH₃-26/27), 0.73 (6H, s, CH₃-19) ppm.





¹³C-NMR (CDCl₃, δ): 140.7 (C-5), 128.8 (C-4'), 121.5 (CH-6), 112.4 (C-5'), 77.2 (C-1'), 71.7 (CH-3), 56.4 (CH-14), 52.3 (CH₂-21), 50.6 (CH), 50.0 (CH), 42.7 (C-13), 42.2 (CH₂), 41.7 (CH), 39.2 (CH₂), 39.2 (CH₂), 37.2 (CH₂), 36.5 (C-10), 31.9 (CH), 31.8 (CH₂), 31.6 (CH₂), 30.6 (CH₃-2'/3'), 30.5 (CH₃-2'/3'), 29.3 (CH₂), 27.9 (CH₂), 27.8 (CH), 24.3 (CH₂), 22.7 (CH₃-26/27), 22.5 (CH₃-26/27), 22.4 (CH₂), 21.1 (CH₂), 19.4 (CH₃-18), 12.1 (CH₃-19) ppm.





MS (ESI⁺) (m/z, %): 534.40 (M⁺+Na, 10), 512.42 (M⁺+1, 100), 494.41 (M⁺-OMe, 31).





HRMS (ESI⁺): 512.4211 calculated for C₃₂H₅₄N₃O₂ and found 512.4206.






















































































































































































































3. X-Ray Spectra

3.1. Compound 8

A single crystal of **8** was (Figure 1) analysed by X-ray diffraction and a summary of the crystallographic data and the structure refinement parameters is reported in Table 1. Crystallographic data were collected at room temperature using a Bruker Smart 6000 CCD detector and Cu-K α radiation ($\lambda = 1.54178 \text{ \AA}$) generated by a Incoatec microfocus source equipped with Incoatec Quazar MX optics. The software APEX3 was used for collecting frames of data, indexing reflections, and the determination of lattice parameters, SAINT for integration of intensity of reflections, and SADABS for scaling and empirical absorption correction. The structure was solved by dual-space methods using the program SHELXT. All non-hydrogen atoms were refined with anisotropic thermal parameters by full-matrix least-squares calculations on F^2 using the program SHELXL-2014. Hydrogen atoms were inserted at calculated positions and constrained with isotropic thermal parameters except for the hydrogen atom of the hydroxyl groups. Drawings were produced with PLATON.




Figure 1. Balls and sticks structure for **8**

Empirical formula	C ₃₂ H ₅₆ O ₃	
Formula weight	488.76	
Temperature	296(2) K	
Wavelength	1.54178 Å	
Crystal system	Monoclinic	
Space group	P2 ₁	
Unit cell dimensions	a = 11.6603(7) Å	a = 90°
	b = 6.3016(4) Å	b = 91.932(5)°
	c = 20.6766(13) Å	g = 90°
Volume	1518.42(16) Å ³	
Z	2	
Density (calculated)	1.069 Mg/m ³	
Absorption coefficient	0.504 mm ⁻¹	
F(000)	544	
Crystal size	0.276 x 0.051 x 0.022 mm ³	
Theta range for data collection	2.138 to 50.561°	
Index ranges	-11 ≤ h ≤ 11, -6 ≤ k ≤ 6, -20 ≤ l ≤ 20	
Reflections collected	8868	
Independent reflections	3165 [R(int) = 0.1098]	
Completeness to theta = 50.561°	99.8 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.7500 and 0.5978	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	3165 / 4 / 331	
Goodness-of-fit on F ²	0.991	
Final R indices [I > 2σ(I)]	R ₁ = 0.0900, wR ₂ = 0.2254	
R indices (all data)	R ₁ = 0.1229, wR ₂ = 0.2573	
Absolute structure parameter	-0.1(10)	
Extinction coefficient	n/a	
Largest diff. peak and hole	0.482 and -0.195 e.Å ⁻³	

Table 1. Crystal data and structure refinement for **8**


3.1. hROR γ LBD - 4

hRORγ LBD - 4	
Data Processing	
X-ray source	ESRF ID23-2
Resolution (Å)	40.83-2.3
Crystal space group	P6 ₁
Unit cell (a, b, c (Å)), α , β , γ (°)	99.381, 99.381, 129.308, 90, 90, 120
Unique reflections	32145
Mean redundancy	9.7
Completeness (%)	99.17
Mean I/ σ	8.18
CC _{1/2}	0.97
Refinement	
N° reflections	31889
Rwork (%)	18.33
Rfree (%)	24.06
N° of non H-atoms	
Macromolecules	3853
Ligands	84
Water	195
R.m.s.d. bond length (Å)	0.007
R.m.s.d. bond angles (°)	0.85
B-factor	
Macromolecules	67.15
Ligands	81.35
Water	68.43

Table 2. Data collection and refinement statistics


4. Supplementary figures

4.1. Supplementary figure 1




(A) Superposition of the two monomers of ROR γ -4. Ligand 4 of monomer A (B) and of monomer B (C) modelled into the unbiased omit Polder map contoured at 3.0 σ .

4.2. Supplementary figure 2



(A) Superimposition of the structures of hROR γ -4 (blue) to the hROR γ LBD-25HC-SRC2-2 CoA (ROR γ in green and CoA in pink). (B) Overlay of **4** (in orange) and 25HC (in green) within ROR γ LBPs. Residues forming hydrogen bonds (red dashed lines) are shown and labeled. Indicated distances are in Å. Red spheres correspond to water molecules. (C) Details of interactions between LBP and **4** in blue and between LBP and 25HC in green at 4.0 Å cut-off. Amino acids (C393, L483, L476, M358 and L362) forming specific interactions with **4** compared to 25HC are underlined in blue. Amino acids forming stronger (F377, F388, I397) or specific interaction (W317) interactions with 25HC compared to **4** are underlined in green.

4.3. Supplementary figure 3



Superposition of the ligands in the 4-bound LBP. Ligands are shown in stick representation with compound 4 in orange.